SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
|
|
AEGON N.V.
|
|
|
|
|
|
|
(Registrant)
|
|
|
|
|
Date: May 8, 2013
|
|
|
|
By
|
|
/s/ E. Lagendijk
|
|
|
|
|
|
|
E. Lagendijk
|
|
|
|
|
|
|
Executive Vice President and General Counsel
|
Condensed consolidated
interim financial statements
Q1 2013
|
|
|
aegon.com
|
|
The Hague, May 8, 2013
|
Table of contents
|
|
|
|
|
|
|
|
|
|
|
|
|
Condensed consolidated income statement
|
|
|
|
|
|
|
|
|
|
|
|
EUR millions
|
|
|
Notes
|
|
|
|
Q1 2013
|
|
|
|
Q1 2012
|
|
|
|
|
|
Premium income
|
|
|
4
|
|
|
|
6,267
|
|
|
|
5,690
|
|
Investment income
|
|
|
5
|
|
|
|
2,013
|
|
|
|
2,060
|
|
Fee and commission income
|
|
|
|
|
|
|
466
|
|
|
|
455
|
|
Other revenues
|
|
|
|
|
|
|
2
|
|
|
|
2
|
|
Total revenues
|
|
|
|
|
|
|
8,748
|
|
|
|
8,207
|
|
Income from reinsurance ceded
|
|
|
|
|
|
|
803
|
|
|
|
946
|
|
Results from financial transactions
|
|
|
6
|
|
|
|
7,731
|
|
|
|
7,556
|
|
Other income
|
|
|
7
|
|
|
|
87
|
|
|
|
-
|
|
Total income
|
|
|
|
|
|
|
17,369
|
|
|
|
16,709
|
|
|
|
|
|
Benefits and expenses
|
|
|
8
|
|
|
|
16,909
|
|
|
|
15,944
|
|
Impairment charges / (reversals)
|
|
|
9
|
|
|
|
25
|
|
|
|
46
|
|
Interest charges and related fees
|
|
|
|
|
|
|
103
|
|
|
|
141
|
|
Other charges
|
|
|
10
|
|
|
|
95
|
|
|
|
18
|
|
Total charges
|
|
|
|
|
|
|
17,132
|
|
|
|
16,149
|
|
|
|
|
|
Share in net result of joint ventures
|
|
|
|
|
|
|
(8
|
)
|
|
|
(3
|
)
|
Share in net result of associates
|
|
|
|
|
|
|
5
|
|
|
|
11
|
|
Income before tax
|
|
|
|
|
|
|
234
|
|
|
|
568
|
|
Income tax (expense) / benefit
|
|
|
|
|
|
|
(30
|
)
|
|
|
(43
|
)
|
Net income
|
|
|
|
|
|
|
204
|
|
|
|
525
|
|
|
|
|
|
Net income attributable to:
|
|
|
|
|
|
|
|
|
|
|
|
|
Equity holders of Aegon N.V.
|
|
|
|
|
|
|
204
|
|
|
|
525
|
|
Non-controlling interests
|
|
|
|
|
|
|
-
|
|
|
|
-
|
|
|
|
|
|
Earnings per share
(EUR per share)
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic earnings per share
|
|
|
|
|
|
|
0.08
|
|
|
|
0.25
|
|
Diluted earnings per share
|
|
|
17
|
|
|
|
0.08
|
|
|
|
0.25
|
|
|
|
|
|
Earnings per common share calculation
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income attributable to equity holders of Aegon N.V.
|
|
|
|
|
|
|
204
|
|
|
|
525
|
|
Coupons on other equity
instruments
|
|
|
|
|
|
|
(49
|
)
|
|
|
(47
|
)
|
Earnings attributable to common shareholders
|
|
|
|
|
|
|
155
|
|
|
|
478
|
|
|
|
|
|
Weighted average number of common shares
outstanding (in million)
|
|
|
|
|
|
|
1,943
|
|
|
|
1,880
|
|
Amounts for 2012 have been restated for the change in accounting policy as disclosed in note 2.
|
|
|
|
|
|
|
|
|
Condensed consolidated statement of comprehensive income
|
|
EUR millions
|
|
Q1 2013
|
|
|
Q1 2012
|
|
|
|
|
Net income
|
|
|
204
|
|
|
|
525
|
|
|
|
|
Other comprehensive income:
|
|
|
|
|
|
|
|
|
Items that will not be reclassified to profit or loss:
|
|
|
|
|
|
|
|
|
Changes in revaluation reserve real estate held for own use
|
|
|
1
|
|
|
|
-
|
|
Remeasurements of defined benefit plans
|
|
|
122
|
|
|
|
(44
|
)
|
Income tax relating to items that will not be reclassified
|
|
|
(50
|
)
|
|
|
(3
|
)
|
|
|
|
Items that may be reclassified subsequently to profit or
loss:
|
|
|
|
|
|
|
|
|
Gains / (losses) on revaluation of available-for-sale investments
|
|
|
(334
|
)
|
|
|
432
|
|
(Gains) / losses transferred to the income statement on disposal and impairment of
available-for-sale investments
|
|
|
(113
|
)
|
|
|
(34
|
)
|
Changes in cash flow hedging reserve
|
|
|
(95
|
)
|
|
|
(330
|
)
|
Movement in foreign currency translation and net foreign investment hedging
reserve
|
|
|
235
|
|
|
|
(292
|
)
|
Equity movements of joint ventures
|
|
|
10
|
|
|
|
14
|
|
Equity movements of associates
|
|
|
10
|
|
|
|
17
|
|
Income tax relating to items that may be reclassified
|
|
|
164
|
|
|
|
20
|
|
Other
|
|
|
3
|
|
|
|
2
|
|
Other comprehensive income for the period
|
|
|
(47
|
)
|
|
|
(218
|
)
|
Total comprehensive income
|
|
|
157
|
|
|
|
307
|
|
|
|
|
Total comprehensive income attributable to:
|
|
|
|
|
|
|
|
|
Equity holders of Aegon N.V.
|
|
|
158
|
|
|
|
307
|
|
Non-controlling interests
|
|
|
(1
|
)
|
|
|
-
|
|
Amounts for 2012 have been restated for the change in accounting policy as disclosed in note 2.
|
|
|
|
|
|
|
|
|
|
|
|
|
Condensed
consolidated statement of financial position
|
|
|
|
|
|
|
Mar. 31,
2013
|
|
|
Dec. 31,
2012
|
|
EUR millions
|
|
|
Notes
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Assets
|
|
|
|
|
|
|
|
|
|
|
|
|
Intangible assets
|
|
|
11
|
|
|
|
2,506
|
|
|
|
2,485
|
|
Investments
|
|
|
12
|
|
|
|
145,718
|
|
|
|
145,021
|
|
Investments for account of policyholders
|
|
|
13
|
|
|
|
159,563
|
|
|
|
152,968
|
|
Derivatives
|
|
|
14
|
|
|
|
19,006
|
|
|
|
21,134
|
|
Investments in joint ventures
|
|
|
|
|
|
|
1,569
|
|
|
|
1,568
|
|
Investments in associates
|
|
|
|
|
|
|
791
|
|
|
|
771
|
|
Reinsurance assets
|
|
|
|
|
|
|
11,966
|
|
|
|
11,965
|
|
Deferred expenses and rebates
|
|
|
16
|
|
|
|
11,868
|
|
|
|
11,644
|
|
Other assets and receivables
|
|
|
|
|
|
|
8,120
|
|
|
|
7,738
|
|
Cash and cash equivalents
|
|
|
|
|
|
|
8,572
|
|
|
|
9,590
|
|
Total assets
|
|
|
|
|
|
|
369,679
|
|
|
|
364,884
|
|
|
|
|
|
Equity and liabilities
|
|
|
|
|
|
|
|
|
|
|
|
|
Shareholders equity
|
|
|
|
|
|
|
23,600
|
|
|
|
23,488
|
|
Other equity instruments
|
|
|
|
|
|
|
5,030
|
|
|
|
5,018
|
|
Issued capital and reserves attributable to equity holders of Aegon
N.V.
|
|
|
|
|
|
|
28,630
|
|
|
|
28,506
|
|
Non-controlling interests
|
|
|
|
|
|
|
12
|
|
|
|
13
|
|
Group equity
|
|
|
|
|
|
|
28,642
|
|
|
|
28,519
|
|
|
|
|
|
Trust pass-through securities
|
|
|
|
|
|
|
156
|
|
|
|
155
|
|
Subordinated borrowings
|
|
|
|
|
|
|
44
|
|
|
|
42
|
|
Insurance contracts
|
|
|
|
|
|
|
106,316
|
|
|
|
104,004
|
|
Insurance contracts for account of policyholders
|
|
|
|
|
|
|
80,657
|
|
|
|
76,169
|
|
Investment contracts
|
|
|
|
|
|
|
16,646
|
|
|
|
17,767
|
|
Investment contracts for account of policyholders
|
|
|
|
|
|
|
81,498
|
|
|
|
78,418
|
|
Derivatives
|
|
|
14
|
|
|
|
16,330
|
|
|
|
18,052
|
|
Borrowings
|
|
|
18
|
|
|
|
13,941
|
|
|
|
13,742
|
|
Other liabilities
|
|
|
|
|
|
|
25,449
|
|
|
|
28,016
|
|
Total
liabilities
|
|
|
|
|
|
|
341,037
|
|
|
|
336,365
|
|
Total equity and
liabilities
|
|
|
|
|
|
|
369,679
|
|
|
|
364,884
|
|
Amounts for 2012 have been restated for the change in accounting policy as disclosed in note 2.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Condensed
consolidated statement of changes in equity
|
|
EUR millions
|
|
Share
capital
1
|
|
|
Retained
earnings
|
|
|
Revaluation
reserves
|
|
|
Remeasurement
of defined
benefit plans
|
|
|
Other
reserves
|
|
|
Other equity
instruments
|
|
|
Issued
capital and
reserves
2
|
|
|
Non-
controlling
interests
|
|
|
Total
|
|
|
|
|
|
|
|
|
|
|
|
Three months ended March 31, 2013
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
At beginning of year
|
|
|
9,099
|
|
|
|
10,446
|
|
|
|
6,073
|
|
|
|
(1,085
|
)
|
|
|
(1,045
|
)
|
|
|
5,018
|
|
|
|
28,506
|
|
|
|
13
|
|
|
|
28,519
|
|
|
|
|
|
|
|
|
|
|
|
Net income recognized in the income statement
|
|
|
-
|
|
|
|
204
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
204
|
|
|
|
-
|
|
|
|
204
|
|
|
|
|
|
|
|
|
|
|
|
Other comprehensive income:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Items that will not be reclassified to profit or
loss:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Changes in revaluation reserve real estate held for own use
|
|
|
-
|
|
|
|
-
|
|
|
|
1
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
1
|
|
|
|
-
|
|
|
|
1
|
|
Remeasurements of defined benefit plans
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
122
|
|
|
|
-
|
|
|
|
-
|
|
|
|
122
|
|
|
|
-
|
|
|
|
122
|
|
Income tax relating to items that will not be reclassified
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
(50
|
)
|
|
|
-
|
|
|
|
-
|
|
|
|
(50
|
)
|
|
|
-
|
|
|
|
(50
|
)
|
|
|
|
|
|
|
|
|
|
|
Items that may be reclassified subsequently to profit or
loss:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gains / (losses) on revaluation of available-for-sale investments
|
|
|
-
|
|
|
|
-
|
|
|
|
(334
|
)
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
(334
|
)
|
|
|
-
|
|
|
|
(334
|
)
|
(Gains) / losses transferred to income statement on disposal and impairment of
available-for-sale investments
|
|
|
-
|
|
|
|
-
|
|
|
|
(113
|
)
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
(113
|
)
|
|
|
-
|
|
|
|
(113
|
)
|
Changes in cash flow hedging reserve
|
|
|
-
|
|
|
|
-
|
|
|
|
(95
|
)
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
(95
|
)
|
|
|
-
|
|
|
|
(95
|
)
|
Movement in foreign currency translation and net foreign investment hedging
reserves
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
(7
|
)
|
|
|
242
|
|
|
|
-
|
|
|
|
235
|
|
|
|
-
|
|
|
|
235
|
|
Equity movements of joint ventures
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
10
|
|
|
|
-
|
|
|
|
10
|
|
|
|
-
|
|
|
|
10
|
|
Equity movements of associates
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
10
|
|
|
|
-
|
|
|
|
10
|
|
|
|
-
|
|
|
|
10
|
|
Income tax relating to items that may be reclassified
|
|
|
-
|
|
|
|
-
|
|
|
|
187
|
|
|
|
-
|
|
|
|
(23
|
)
|
|
|
-
|
|
|
|
164
|
|
|
|
-
|
|
|
|
164
|
|
Transfer from / to other headings
|
|
|
-
|
|
|
|
(2
|
)
|
|
|
2
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
Other
|
|
|
-
|
|
|
|
4
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
4
|
|
|
|
(1
|
)
|
|
|
3
|
|
Total other comprehensive
income
|
|
|
-
|
|
|
|
2
|
|
|
|
(352
|
)
|
|
|
65
|
|
|
|
239
|
|
|
|
-
|
|
|
|
(46
|
)
|
|
|
(1
|
)
|
|
|
(47
|
)
|
Total comprehensive income/ (loss) for 2013
|
|
|
-
|
|
|
|
206
|
|
|
|
(352
|
)
|
|
|
65
|
|
|
|
239
|
|
|
|
-
|
|
|
|
158
|
|
|
|
(1
|
)
|
|
|
157
|
|
|
|
|
|
|
|
|
|
|
|
Coupons on non-cumulative subordinated notes
|
|
|
-
|
|
|
|
(6
|
)
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
(6
|
)
|
|
|
-
|
|
|
|
(6
|
)
|
Coupons on perpetual securities
|
|
|
-
|
|
|
|
(43
|
)
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
(43
|
)
|
|
|
-
|
|
|
|
(43
|
)
|
Share options and incentive plans
|
|
|
-
|
|
|
|
3
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
12
|
|
|
|
15
|
|
|
|
-
|
|
|
|
15
|
|
At end of period
|
|
|
9,099
|
|
|
|
10,606
|
|
|
|
5,721
|
|
|
|
(1,020
|
)
|
|
|
(806
|
)
|
|
|
5,030
|
|
|
|
28,630
|
|
|
|
12
|
|
|
|
28,642
|
|
|
|
|
|
|
|
|
|
|
|
Three months ended March 31, 2012
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
At beginning of year (as previously stated)
|
|
|
9,097
|
|
|
|
9,403
|
|
|
|
3,464
|
|
|
|
-
|
|
|
|
(964
|
)
|
|
|
4,720
|
|
|
|
25,720
|
|
|
|
14
|
|
|
|
25,734
|
|
|
|
|
|
|
|
|
|
|
|
Changes in accounting policies relating to IFRS 10
|
|
|
-
|
|
|
|
(122
|
)
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
(122
|
)
|
|
|
-
|
|
|
|
(122
|
)
|
Changes in accounting policies relating to IFRS 11
|
|
|
-
|
|
|
|
-
|
|
|
|
17
|
|
|
|
-
|
|
|
|
(17
|
)
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
Changes in accounting policies relating to IAS
19
|
|
|
-
|
|
|
|
15
|
|
|
|
-
|
|
|
|
(979
|
)
|
|
|
-
|
|
|
|
-
|
|
|
|
(964
|
)
|
|
|
-
|
|
|
|
(964
|
)
|
|
|
|
|
|
|
|
|
|
|
At beginning of year, restated
|
|
|
9,097
|
|
|
|
9,296
|
|
|
|
3,481
|
|
|
|
(979
|
)
|
|
|
(981
|
)
|
|
|
4,720
|
|
|
|
24,634
|
|
|
|
14
|
|
|
|
24,648
|
|
|
|
|
|
|
|
|
|
|
|
Net income recognized in the income statement
|
|
|
-
|
|
|
|
525
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
525
|
|
|
|
-
|
|
|
|
525
|
|
|
|
|
|
|
|
|
|
|
|
Other comprehensive income:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Items that will not be reclassified to profit or loss:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Remeasurements of defined benefit plans
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
(44
|
)
|
|
|
-
|
|
|
|
-
|
|
|
|
(44
|
)
|
|
|
-
|
|
|
|
(44
|
)
|
Income tax relating to items that will not be reclassified
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
(3
|
)
|
|
|
-
|
|
|
|
-
|
|
|
|
(3
|
)
|
|
|
-
|
|
|
|
(3
|
)
|
|
|
|
|
|
|
|
|
|
|
Items that may be reclassified subsequently to profit or
loss:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gains / (losses) on revaluation of available-for-sale investments
|
|
|
-
|
|
|
|
-
|
|
|
|
432
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
432
|
|
|
|
-
|
|
|
|
432
|
|
(Gains) / losses transferred to income statement on disposal and impairment of
available-for-sale investments
|
|
|
-
|
|
|
|
-
|
|
|
|
(34
|
)
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
(34
|
)
|
|
|
-
|
|
|
|
(34
|
)
|
Changes in cash flow hedging reserve
|
|
|
-
|
|
|
|
-
|
|
|
|
(330
|
)
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
(330
|
)
|
|
|
-
|
|
|
|
(330
|
)
|
Movement in foreign currency translation and net foreign investment hedging
reserves
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
13
|
|
|
|
(305
|
)
|
|
|
-
|
|
|
|
(292
|
)
|
|
|
-
|
|
|
|
(292
|
)
|
Equity movements of joint ventures
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
14
|
|
|
|
-
|
|
|
|
14
|
|
|
|
-
|
|
|
|
14
|
|
Equity movements of associates
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
17
|
|
|
|
-
|
|
|
|
17
|
|
|
|
-
|
|
|
|
17
|
|
Income tax relating to items that may be reclassified
|
|
|
-
|
|
|
|
-
|
|
|
|
3
|
|
|
|
-
|
|
|
|
19
|
|
|
|
(2
|
)
|
|
|
20
|
|
|
|
-
|
|
|
|
20
|
|
Transfer from / to other headings
|
|
|
-
|
|
|
|
(17
|
)
|
|
|
17
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
Other
|
|
|
-
|
|
|
|
2
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
2
|
|
|
|
-
|
|
|
|
2
|
|
Total other comprehensive
income
|
|
|
-
|
|
|
|
(15
|
)
|
|
|
88
|
|
|
|
(34
|
)
|
|
|
(255
|
)
|
|
|
(2
|
)
|
|
|
(218
|
)
|
|
|
-
|
|
|
|
(218
|
)
|
Total comprehensive income / (loss) for 2012
|
|
|
-
|
|
|
|
510
|
|
|
|
88
|
|
|
|
(34
|
)
|
|
|
(255
|
)
|
|
|
(2
|
)
|
|
|
307
|
|
|
|
-
|
|
|
|
307
|
|
|
|
|
|
|
|
|
|
|
|
Issuance of non-cumulative subordinated loans
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
271
|
|
|
|
271
|
|
|
|
-
|
|
|
|
271
|
|
Coupons on non-cumulative subordinated notes
|
|
|
-
|
|
|
|
(3
|
)
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
(3
|
)
|
|
|
-
|
|
|
|
(3
|
)
|
Coupons on perpetual securities
|
|
|
-
|
|
|
|
(44
|
)
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
(44
|
)
|
|
|
-
|
|
|
|
(44
|
)
|
Cost of issuance of non-cumulative subordinated notes (net of tax)
|
|
|
-
|
|
|
|
(9
|
)
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
(9
|
)
|
|
|
-
|
|
|
|
(9
|
)
|
Share options and incentive plans
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
9
|
|
|
|
9
|
|
|
|
-
|
|
|
|
9
|
|
At end of period
|
|
|
9,097
|
|
|
|
9,750
|
|
|
|
3,569
|
|
|
|
(1,013
|
)
|
|
|
(1,236
|
)
|
|
|
4,998
|
|
|
|
25,165
|
|
|
|
14
|
|
|
|
25,179
|
|
1
For a breakdown of share capital please refer to note 18.
2
Issued capital and reserves attributable to equity holders of Aegon N.V.
Amounts for 2012 have been restated for the change in accounting policy as disclosed in note 2.
|
|
|
|
|
|
|
|
|
Condensed consolidated cash flow statement
|
|
EUR millions
|
|
Q1 2013
|
|
|
Q1 2012
|
|
|
|
|
Cash flow from operating activities
|
|
|
(1,073
|
)
|
|
|
(693
|
)
|
|
|
|
Purchases and disposals of intangible assets
|
|
|
(1
|
)
|
|
|
(10
|
)
|
Purchases and disposals of equipment and other assets
|
|
|
(10
|
)
|
|
|
(13
|
)
|
Purchases, disposals and dividends of
subsidiaries, associates and joint ventures
|
|
|
(21
|
)
|
|
|
(4
|
)
|
Cash flow from investing activities
|
|
|
(32
|
)
|
|
|
(27
|
)
|
|
|
|
Issuances, repurchases and coupons of perpetuals
|
|
|
(57
|
)
|
|
|
(58
|
)
|
Issuances, repurchases and coupons of non-cumulative subordinated
notes
|
|
|
(8
|
)
|
|
|
266
|
|
Issuances and repayments of
borrowings
|
|
|
58
|
|
|
|
1,299
|
|
Cash flow from financing activities
|
|
|
(7
|
)
|
|
|
1,507
|
|
|
|
|
Net increase / (decrease) in cash and cash
equivalents
|
|
|
(1,112
|
)
|
|
|
787
|
|
Net cash and cash equivalents at January 1
|
|
|
9,497
|
|
|
|
7,717
|
|
Effects of changes in foreign exchange
rates
|
|
|
(6
|
)
|
|
|
(15
|
)
|
Net cash and cash equivalents at end of
period
|
|
|
8,379
|
|
|
|
8,489
|
|
|
|
|
|
|
Mar. 31,
2013
|
|
|
Mar. 31,
2012
|
|
Cash and cash equivalents
|
|
|
8,572
|
|
|
|
8,591
|
|
Bank overdrafts
|
|
|
(193
|
)
|
|
|
(102
|
)
|
Net cash and cash
equivalents
|
|
|
8,379
|
|
|
|
8,489
|
|
Amounts for 2012 have been restated for the change in accounting policy as disclosed in note 2.
Notes to the condensed consolidated interim financial statements
Amounts in EUR millions, unless otherwise stated
Aegon N.V., incorporated and domiciled in the Netherlands, is a public limited liability company organized under Dutch law and recorded in the Commercial Register of The Hague under number 27076669 and with its
registered address at Aegonplein 50, 2591 TV, The Hague, the Netherlands. Aegon N.V. serves as the holding company for the Aegon Group and has listings of its common shares in Amsterdam and New York.
Aegon N.V. (or the company) and its consolidated subsidiaries (Aegon or the Group) have life insurance and pensions operations
in over twenty countries in the Americas, Europe and Asia and are also active in savings and asset management operations, accident and health insurance, general insurance and to a limited extent banking operations. Its headquarters are located
in The Hague, the Netherlands. The Group employs approximately 24,500 people worldwide (2012: 24,500).
1. Basis of presentation
The condensed consolidated interim financial statements as at, and for the first quarter ended, March 31, 2013, have been prepared in
accordance with IAS 34 Interim financial reporting, as adopted by the European Union (hereafter IFRS). They do not include all of the information required for a full set of financial statements prepared in accordance with
IFRS and should therefore be read together with the 2012 consolidated financial statements of Aegon N.V. as included in Aegons Annual Report for 2012. Aegons Annual Report for 2012 is available on its website (aegon.com).
The condensed consolidated interim financial statements have been prepared in accordance with the historical cost convention as modified by the revaluation of
investment properties and those financial instruments (including derivatives) and financial liabilities that have been measured at fair value. Certain amounts in prior periods have been reclassified to conform to the current year presentation. These
reclassifications had no effect on net income, shareholders equity or earnings per share. The condensed consolidated interim financial statements as at, and for the first quarter ended, March 31, 2013 were approved by the Executive Board
on May 6, 2013.
The published figures in these condensed consolidated interim financial statements are unaudited.
2. Significant accounting policies
The
accounting policies and methods of computation applied in the condensed consolidated interim financial statements are the same as those applied in the 2012 consolidated financial statements, except for the newly applied accounting policies.
Adoption of new accounting policies
Aegon
applies new and amended standards that require restatement of previous financial statements. These include IFRS 10 Consolidated Financial Statements, IFRS 11 Joint Arrangements, IAS 19 (revised 2011) Employee
Benefits and IAS 1 Presentation of Financial Statements. Application of IFRS 13 Fair Value Measurement is required prospectively as of the beginning of the annual reporting period.
The nature and the impact of each new standard/amendment that has been applied for the first time in 2013 is described below:
t
|
|
IFRS 7, Financial Instruments: Disclosures Offsetting Financial Assets and Financial Liabilities: The amendments to IFRS 7 enable users of the
financial statements to evaluate the effect or potential effect of netting arrangements, including rights of set-off associated with the entitys recognized financial assets and recognized financial liabilities, on the entitys financial
position. The amendment affects disclosure only and is included in note 19.
|
t
|
|
IFRS 10, Consolidated financial statements: IFRS 10 replaces all the guidance on control and consolidation in IAS 27, Consolidated and separate
financial statements, and SIC-12, Consolidation special purpose entities. The application of this new standard impacted the financial position of Aegon by consolidating one securitization vehicle that was previously not
consolidated. In addition for several investment funds the consolidation conclusion has been revisited which resulted in changes compared to previous years. The impact of the adoption of IFRS 10 on the financial position of Aegon is described in
note 2.1.
|
t
|
|
IFRS 11, Joint Arrangements: IFRS 11 replaces IAS 31 Interests in Joint Ventures and SIC-13 Jointly-controlled Entities Non-monetary
Contributions by Venturers. IFRS 11 removes the option to account for jointly controlled entities (JCEs) using proportionate consolidation. Instead, JCEs that meet the definition of a joint venture under IFRS 11 must be accounted for using the
equity method. The effect of this standard is that Aegon starts to account for its joint ventures on a net equity value basis. The impact of the adoption of IFRS 11 on the financial position of Aegon is described in note 2.1.
|
t
|
|
IFRS 12, Disclosure of interests in other entities: IFRS 12 provides disclosure requirements on interests in subsidiaries, associates, joint
ventures, and structured entities. This standard affects disclosure only and has therefore no impact on Aegons financial position or performance. Aegon will provide the disclosures in the annual report 2013 as required.
|
t
|
|
IFRS 13, Fair Value Measurement: IFRS 13 establishes a single source of guidance under IFRS for all fair value measurements. IFRS 13 does not change
when an entity is required to use fair value, but rather provides guidance on how to measure fair value under IFRS when fair value is required or permitted. The application of IFRS 13 has not impacted the fair value measurements carried out by the
Group, which is described in note 2.3. IFRS 13 also requires specific disclosures on fair values, some of which replace existing disclosure requirements in other standards, including IFRS 7 Financial Instruments: Disclosures. Some of these
disclosures, specifically for financial instruments, are required in interim condensed consolidated financial statements. Aegon provides these disclosures in note 15.
|
t
|
|
IAS 1, Financial Statement Presentation Presentation of Items of Other Comprehensive Income: The amendments require the grouping of items
within other comprehensive income that may be reclassified to the profit or loss section of the income statement. The amendments also reaffirm existing requirements that items in other comprehensive income and profit or loss should be presented as
either a single statement or two consecutive statements. The amendment affects presentation only and changes are included in the condensed statement of comprehensive income.
|
t
|
|
IAS 19, Employee Benefits: The revised standard eliminates the option to defer the recognition of actuarial gains and losses, known as the
corridor method. The amendments streamline the presentation of changes in assets and liabilities arising from defined benefit plans, including requiring remeasurements to be presented in other comprehensive income, to immediately
recognize all past service costs and to replace interest cost and expected return on plan assets with a net interest amount that is calculated by applying the discount rate to the net defined benefit liability (asset). The impact of the adoption of
the revised IAS 19 on the financial position of Aegon is described in note 2.2.
|
t
|
|
IAS 27, Separate financial statements: IAS 27 was amended following the issuance of IFRS 10. The revised IAS 27 deals only with the accounting for
subsidiaries, associates and joint ventures in the separate financial statements of the parent company. The application of the amendments has not impacted the financial position of the Group.
|
t
|
|
IAS 28, Investments in Associates and Joint Ventures: IAS 28 was amended following the issuance of IFRS 10 and IFRS 11. The revised IAS 28 describes
the application of the equity method to investments in joint ventures in addition to associates. The application of the amendments has not impacted the financial position of the Group.
|
For a complete overview of IFRS standards, published before January 1, 2013, that will be applied in future years, but were not early adopted by the Group,
please refer to Aegons Annual Report for 2012.
Taxes
Taxes on income for the Q1 2013 interim period are accrued using the tax rate that would be applicable to expected total annual earnings.
Judgments and critical accounting estimates
Preparing the condensed consolidated interim financial statements requires management to make judgments, estimates and assumptions, including the likelihood, timing or amount of future transactions or events, that
affect the application of accounting policies and the reported amounts of assets and liabilities, income and expense. Actual results may differ from the estimates made.
In preparing the condensed consolidated interim financial statements, significant judgments made by management in applying the Groups accounting policies and the key sources of estimation uncertainty were the
same as those that applied to the consolidated financial statements as at and for the year ended December 31, 2012.
Exchange rates
Assets and liabilities are translated at the closing rates on the balance sheet date. Income, expenses and capital transactions (such as dividends)
are translated at average exchange rates or at the prevailing rates on the transaction date, if more appropriate. The following exchange rates are applied for the condensed consolidated interim financial statements:
Closing exchange rates
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
USD
|
|
|
|
GBP
|
|
March 31, 2013
|
|
|
1
|
|
|
|
EUR
|
|
|
|
1.2841
|
|
|
|
0.8456
|
|
December 31, 2012
|
|
|
1
|
|
|
|
EUR
|
|
|
|
1.3184
|
|
|
|
0.8111
|
|
Weighted average exchange rates
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
USD
|
|
|
|
GBP
|
|
Q1 2013
|
|
|
1
|
|
|
|
EUR
|
|
|
|
1.3195
|
|
|
|
0.8506
|
|
Q1 2012
|
|
|
1
|
|
|
|
EUR
|
|
|
|
1.3101
|
|
|
|
0.8335
|
|
2.1 Changes in accounting policies for consolidation and joint arrangements
Aegon has early adopted IFRS 10 - Consolidated Financial Statements on January 1, 2013. Aegon also adopted IFRS 11, Joint Arrangements,
IFRS 12, Disclosure of Interests in Other Entities, and consequential amendments to IAS 27, Separate financial statements and IAS 28, Investments in Associates and Joint Ventures, at the same time.
a. Subsidiaries
IFRS 10 changes the
definition of control such that an investor controls an investee when it is exposed, or has rights, to variable returns from its involvement with the investee and has the ability to affect those returns through its power over the investee. To meet
the definition of control in IFRS 10, all three criteria must be met, including: (a) an investor has power over an investee; (b) the investor has exposure, or rights, to variable returns from its involvement with the investee; and
(c) the investor has the ability to use its power over the investee to affect the amount of the investors returns.
Aegon has applied the new
standard retrospectively, in accordance with the transitional provisions of IFRS 10. The application of this new standard impacted the financial position of Aegon by consolidating one securitization vehicle that was previously not consolidated. In
addition, for several investment funds the consolidation conclusion has been revisited which resulted in changes compared to previous years. The effect of the change in accounting policies for consolidation on the financial position, comprehensive
income and the cash flows of Aegon at January 1, 2012, and December 31, 2012, are summarized together with the impact of IFRS 11 and revised IAS 19 in note 2.4.
b. Joint arrangements
IFRS 11 replaces IAS 31 Interests in Joint Ventures and SIC-13 Jointly-controlled Entities Non-monetary Contributions by Venturers. IFRS 11 removes the option to account for jointly controlled entities
(JCEs) using proportionate consolidation. Instead, JCEs that meet the definition of a joint venture under IFRS 11 must be accounted for using the equity method.
In general, joint arrangements are contractual agreements whereby the Group undertakes with other parties an economic activity that is subject to joint control. Joint control exists when it is contractually agreed
to share control of an economic activity. Joint control exists only when decisions about the relevant activities require the unanimous consent of the parties sharing control.
Aegon has early adopted IFRS 11 - Joint Arrangements, on January 1, 2013. Under IFRS 11 investments in joint arrangements are classified as either joint operations or joint ventures depending on the
contractual rights and obligations each investor has rather than the legal structure of the joint arrangement. Aegon has assessed the nature of its joint arrangements and determined them to be joint ventures. The joint ventures will be accounted for
using the equity method and are no longer proportionately consolidated.
Aegon has applied the new policies for interests in joint ventures occurring on
or after January 1, 2012, in accordance with the transition provisions of IFRS 11. The effects of the change in accounting policies for joint arrangements on the financial position of the group are summarized in note 2.4.
2.2 Changes in accounting policies for assets and liabilities relating to employee benefits
Aegon adopted IAS 19 - Employee Benefits, on January 1, 2013. As a result, Aegon changed its accounting policies for the assets and liabilities relating to
employee benefits.
Aegon has applied the new policies for employee benefits retrospectively in accordance with the transitional provisions of the
revised IAS 19. Aegons accounting policies for assets and liabilities relating to employee benefits as set out below reflect the changes under the revised IAS 19.
a. Short-term employee benefits
Prior to January 1, 2013, short-term benefits were
recognized based on the employees entitlement to the benefits. Under the revised IAS 19 a liability is recognized for the undiscounted amount of short-term employee absences benefits expected to be settled within one year after the end of the
period in which the service was rendered. Accumulating short-term absences are recognized over the period in which the service is provided. Benefits that are not service-related are recognized when the event that gives rise to the obligation occurs.
This change in accounting policies has no impact on Aegons financial position.
b. Post-employment benefits
The Group has issued defined contribution plans and defined benefit plans. A plan is classified as a defined contribution plan when the Group has no further
obligation than the payment of a fixed contribution. All other plans are classified as defined benefit plans.
Defined contribution plans
The contribution payable to a defined contribution plan for services provided is recognized as an expense in the income statement. An asset is
recognized to the extent that the contribution paid exceeds the amount due for services provided.
Defined benefit plans
Revised IAS 19 includes a number of amendments to the accounting for defined benefit plans, including actuarial gains and losses that are recognized in other comprehensive income and permanently excluded from
profit and loss; expected returns on plan assets that are no longer recognized in profit or loss, instead, there is a requirement to recognize interest on the net defined benefit liability (asset) in profit or loss, calculated using the discount
rate used to measure the defined benefit obligation, and; unvested past service costs are recognized in profit or loss at the earlier of when the amendment occurs or when the related restructuring or termination costs are recognized. Other
amendments include new disclosures, such as, quantitative sensitivity disclosures.
Upon transition to revised IAS 19, Aegon recognizes all actuarial
gains and losses as they occur and therefore no longer applies the corridor approach. Furthermore, past service costs are recognized immediately if the benefits have vested directly after the introduction of, or changes to, a pension plan.
The effects of the change in accounting policies for assets and liabilities relating to employee benefits on the financial position of the Group are
summarized in note 2.4.
2.3 Changes in accounting policies for fair value measurement relating to financial and non-financial
liabilities
Aegon adopted IFRS 13 Fair Value Measurement, on January 1, 2013. This resulted in the Group changing its accounting
policies for the fair value measurement of financial and non-financial liabilities.
IFRS 13 establishes a single source of guidance under IFRS for all
fair value measurements. IFRS 13 does not change when an entity is required to use fair value, but rather provides guidance on how to measure fair value under IFRS when fair value is required or permitted. Under IFRS 13, fair value is defined as the
amount that would be received from the sale of an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date under current market conditions (i.e. an exit price at the measurement date from
the perspective of a market participant that holds the asset or owes the liability). A fair value measurement assumes that the transaction to sell the asset or transfer the liability takes place either:
(a) in the principal market for the asset or liability; or
(b) in
the absence of a principal market, in the most advantageous market for the asset or liability.
The application of IFRS 13 has not impacted Aegons
fair value measurements. The description of Aegons methods of determining fair value is included in the consolidated financial statements 2012 and has not changed under IFRS 13. IFRS 13 requires specific disclosures on fair values, some of
which replace existing disclosure requirements in other standards, including IFRS 7 Financial Instruments: Disclosures. Some of these disclosures, specifically for financial instruments, are required in interim condensed consolidated financial
statements. These disclosures are provided in note 15.
2.4 Impact of changes in accounting policies on the financial position
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Impact
of changes in accounting policies on condensed consolidated income statement
|
|
|
|
Q1 2012
(previously
reported)
|
|
|
Change in
accounting
policy
IFRS 10/11
|
|
|
Change in
accounting
policy
IAS 19
|
|
|
Q1 2012
(restated)
|
|
EUR millions
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total income
|
|
|
16,912
|
|
|
|
(203
|
)
|
|
|
-
|
|
|
|
16,709
|
|
|
|
|
|
|
Total charges
|
|
|
16,360
|
|
|
|
(197
|
)
|
|
|
(14
|
)
|
|
|
16,149
|
|
|
|
|
|
|
Share in net result of joint ventures
|
|
|
-
|
|
|
|
(3
|
)
|
|
|
-
|
|
|
|
(3
|
)
|
Share in net result of associates
|
|
|
11
|
|
|
|
-
|
|
|
|
-
|
|
|
|
11
|
|
Income before tax
|
|
|
563
|
|
|
|
(9
|
)
|
|
|
14
|
|
|
|
568
|
|
Income tax (expense) / benefit
|
|
|
(42
|
)
|
|
|
3
|
|
|
|
(4
|
)
|
|
|
(43
|
)
|
Net income
|
|
|
521
|
|
|
|
(6
|
)
|
|
|
10
|
|
|
|
525
|
|
Net income attributable to:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Equity holders of Aegon N.V.
|
|
|
521
|
|
|
|
(6
|
)
|
|
|
10
|
|
|
|
525
|
|
Non-controlling interests
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
|
|
|
Earnings per share
(EUR per share)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic earnings per share
|
|
|
0.25
|
|
|
|
-
|
|
|
|
-
|
|
|
|
0.25
|
|
Diluted earnings per share
|
|
|
0.25
|
|
|
|
-
|
|
|
|
-
|
|
|
|
0.25
|
|
|
|
|
|
|
Earnings per common share calculation
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income attributable to equity holders of Aegon N.V.
|
|
|
521
|
|
|
|
(6
|
)
|
|
|
10
|
|
|
|
525
|
|
Coupons on other equity
instruments
|
|
|
(47
|
)
|
|
|
-
|
|
|
|
-
|
|
|
|
(47
|
)
|
Earnings attributable to common shareholders
|
|
|
474
|
|
|
|
(6
|
)
|
|
|
10
|
|
|
|
478
|
|
|
|
|
|
|
Weighted average number of common shares
outstanding (in million)
|
|
|
1,880
|
|
|
|
-
|
|
|
|
-
|
|
|
|
1,880
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Impact
of changes in accounting policies on condensed consolidated statement of comprehensive income
|
|
|
|
Q1 2012
(previously
reported)
|
|
|
Change in
accounting
policy
IFRS 10/11
|
|
|
Change in
accounting
policy
IAS 19
|
|
|
Q1 2012
(restated)
|
|
Net income
|
|
|
521
|
|
|
|
(6
|
)
|
|
|
10
|
|
|
|
525
|
|
|
|
|
|
|
Items that will not be reclassified to profit or loss:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Remeasurements of defined benefit plans
|
|
|
-
|
|
|
|
-
|
|
|
|
(44
|
)
|
|
|
(44
|
)
|
Income tax relating to items that will not be reclassified
|
|
|
-
|
|
|
|
-
|
|
|
|
(3
|
)
|
|
|
(3
|
)
|
|
|
|
|
|
Items that may be reclassified to profit or loss:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gains / (losses) on revaluation of available-for-sale investments
|
|
|
453
|
|
|
|
(21
|
)
|
|
|
-
|
|
|
|
432
|
|
Income tax relating to items that may be reclassified
|
|
|
13
|
|
|
|
7
|
|
|
|
-
|
|
|
|
20
|
|
Movement in foreign currency translation and net foreign investment hedging
reserves
|
|
|
(305
|
)
|
|
|
-
|
|
|
|
13
|
|
|
|
(292
|
)
|
Equity movements of joint ventures
|
|
|
-
|
|
|
|
14
|
|
|
|
-
|
|
|
|
14
|
|
Other comprehensive income for the
period
|
|
|
(345
|
)
|
|
|
-
|
|
|
|
-
|
|
|
|
(345
|
)
|
Total other comprehensive income for the period
|
|
|
(184
|
)
|
|
|
-
|
|
|
|
(34
|
)
|
|
|
(218
|
)
|
Total comprehensive income
|
|
|
337
|
|
|
|
(6
|
)
|
|
|
(24
|
)
|
|
|
307
|
|
|
|
|
|
|
Total comprehensive income attributable to:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Equity holders of Aegon N.V.
|
|
|
337
|
|
|
|
(6
|
)
|
|
|
(24
|
)
|
|
|
307
|
|
Non-controlling interests
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Impact
of changes in accounting policies on condensed consolidated statement of financial position
|
|
|
|
January
1, 2012
(previously
reported)
|
|
|
Change in
accounting
policy
IFRS 10/11
|
|
|
Change in
accounting
policy
IAS 19
|
|
|
January
1, 2012
(restated)
|
|
|
December
31, 2012
(previously
reported)
|
|
|
Change in
accounting
policy
IFRS 10/11
|
|
|
Change in
accounting
policy
IAS 19
|
|
|
December
31, 2012
(restated)
|
|
EUR millions
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Assets
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Investments
|
|
|
144,079
|
|
|
|
(1,374
|
)
|
|
|
-
|
|
|
|
142,705
|
|
|
|
146,234
|
|
|
|
(1,213
|
)
|
|
|
-
|
|
|
|
145,021
|
|
Investments for account of policyholders
|
|
|
142,529
|
|
|
|
(866
|
)
|
|
|
-
|
|
|
|
141,663
|
|
|
|
153,670
|
|
|
|
(702
|
)
|
|
|
-
|
|
|
|
152,968
|
|
Investments in joint ventures
|
|
|
-
|
|
|
|
1,224
|
|
|
|
-
|
|
|
|
1,224
|
|
|
|
-
|
|
|
|
1,568
|
|
|
|
-
|
|
|
|
1,568
|
|
Defined benefit assets
|
|
|
303
|
|
|
|
-
|
|
|
|
(285
|
)
|
|
|
18
|
|
|
|
201
|
|
|
|
-
|
|
|
|
(179
|
)
|
|
|
22
|
|
Other assets
|
|
|
58,465
|
|
|
|
(299
|
)
|
|
|
-
|
|
|
|
58,166
|
|
|
|
66,013
|
|
|
|
(708
|
)
|
|
|
-
|
|
|
|
65,305
|
|
Total assets
|
|
|
345,376
|
|
|
|
(1,315
|
)
|
|
|
(285
|
)
|
|
|
343,776
|
|
|
|
366,118
|
|
|
|
(1,055
|
)
|
|
|
(179
|
)
|
|
|
364,884
|
|
|
|
|
|
|
|
|
|
|
Equity and liabilities
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Shareholders equity
|
|
|
21,000
|
|
|
|
(122
|
)
|
|
|
(964
|
)
|
|
|
19,914
|
|
|
|
24,669
|
|
|
|
(154
|
)
|
|
|
(1,027
|
)
|
|
|
23,488
|
|
Other equity instruments
|
|
|
4,720
|
|
|
|
-
|
|
|
|
-
|
|
|
|
4,720
|
|
|
|
5,018
|
|
|
|
-
|
|
|
|
-
|
|
|
|
5,018
|
|
Issued capital and reserves attributable to
equity holders of Aegon N.V.
|
|
|
25,720
|
|
|
|
(122
|
)
|
|
|
(964
|
)
|
|
|
24,634
|
|
|
|
29,687
|
|
|
|
(154
|
)
|
|
|
(1,027
|
)
|
|
|
28,506
|
|
Non-controlling interests
|
|
|
14
|
|
|
|
-
|
|
|
|
-
|
|
|
|
14
|
|
|
|
13
|
|
|
|
-
|
|
|
|
-
|
|
|
|
13
|
|
Group equity
|
|
|
25,734
|
|
|
|
(122
|
)
|
|
|
(964
|
)
|
|
|
24,648
|
|
|
|
29,700
|
|
|
|
(154
|
)
|
|
|
(1,027
|
)
|
|
|
28,519
|
|
|
|
|
|
|
|
|
|
|
Insurance contracts
|
|
|
104,974
|
|
|
|
(1,452
|
)
|
|
|
-
|
|
|
|
103,522
|
|
|
|
105,209
|
|
|
|
(1,205
|
)
|
|
|
-
|
|
|
|
104,004
|
|
Insurance contracts for account of policyholders
|
|
|
73,425
|
|
|
|
(866
|
)
|
|
|
-
|
|
|
|
72,559
|
|
|
|
76,871
|
|
|
|
(702
|
)
|
|
|
-
|
|
|
|
76,169
|
|
Investment contracts
|
|
|
20,847
|
|
|
|
(1
|
)
|
|
|
-
|
|
|
|
20,846
|
|
|
|
17,768
|
|
|
|
(1
|
)
|
|
|
-
|
|
|
|
17,767
|
|
Investment contracts for account of policyholders
|
|
|
71,433
|
|
|
|
-
|
|
|
|
-
|
|
|
|
71,433
|
|
|
|
78,418
|
|
|
|
-
|
|
|
|
-
|
|
|
|
78,418
|
|
Defined benefit obligations
|
|
|
2,184
|
|
|
|
-
|
|
|
|
1,147
|
|
|
|
3,331
|
|
|
|
2,222
|
|
|
|
-
|
|
|
|
1,328
|
|
|
|
3,550
|
|
Deferred tax liabilities
|
|
|
2,499
|
|
|
|
(27
|
)
|
|
|
(468
|
)
|
|
|
2,004
|
|
|
|
3,622
|
|
|
|
(33
|
)
|
|
|
(480
|
)
|
|
|
3,109
|
|
Other liabilities
|
|
|
44,280
|
|
|
|
1,153
|
|
|
|
-
|
|
|
|
45,433
|
|
|
|
52,308
|
|
|
|
1,040
|
|
|
|
-
|
|
|
|
53,348
|
|
Total liabilities
|
|
|
319,642
|
|
|
|
(1,193
|
)
|
|
|
679
|
|
|
|
319,128
|
|
|
|
336,418
|
|
|
|
(901
|
)
|
|
|
848
|
|
|
|
336,365
|
|
Total equity and
liabilities
|
|
|
345,376
|
|
|
|
(1,315
|
)
|
|
|
(285
|
)
|
|
|
343,776
|
|
|
|
366,118
|
|
|
|
(1,055
|
)
|
|
|
(179
|
)
|
|
|
364,884
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Impact
of changes in accounting policies on condensed consolidated statement of changes in equity
|
|
|
|
March
31, 2012
(previously
reported)
|
|
|
Change in
accounting
policy
IFRS 10/11
|
|
|
Change in
accounting
policy
IAS 19
|
|
|
March
31, 2012
(restated)
|
|
|
December
31, 2012
(previously
reported)
|
|
|
Change in
accounting
policy
IFRS 10/11
|
|
|
Change in
accounting
policy
IAS 19
|
|
|
December
31, 2012
(restated)
|
|
EUR millions
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Share capital
|
|
|
9,097
|
|
|
|
-
|
|
|
|
-
|
|
|
|
9,097
|
|
|
|
9,099
|
|
|
|
-
|
|
|
|
-
|
|
|
|
9,099
|
|
Retained earnings
|
|
|
9,853
|
|
|
|
(128
|
)
|
|
|
25
|
|
|
|
9,750
|
|
|
|
10,543
|
|
|
|
(155
|
)
|
|
|
58
|
|
|
|
10,446
|
|
Revaluation reserves
|
|
|
3,566
|
|
|
|
3
|
|
|
|
-
|
|
|
|
3,569
|
|
|
|
6,082
|
|
|
|
(9
|
)
|
|
|
-
|
|
|
|
6,073
|
|
Remeasurement of defined benefit plans
|
|
|
-
|
|
|
|
-
|
|
|
|
(1,013
|
)
|
|
|
(1,013
|
)
|
|
|
-
|
|
|
|
-
|
|
|
|
(1,085
|
)
|
|
|
(1,085
|
)
|
Other reserves
|
|
|
(1,233
|
)
|
|
|
(3
|
)
|
|
|
-
|
|
|
|
(1,236
|
)
|
|
|
(1,055
|
)
|
|
|
10
|
|
|
|
-
|
|
|
|
(1,045
|
)
|
Shareholders equity
|
|
|
21,283
|
|
|
|
(128
|
)
|
|
|
(988
|
)
|
|
|
20,167
|
|
|
|
24,669
|
|
|
|
(154
|
)
|
|
|
(1,027
|
)
|
|
|
23,488
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Impact of
changes in accounting policies on condensed consolidated cash flow statement
|
|
|
|
Q1 2012
(previously
reported)
|
|
|
Change in
accounting
policy
IFRS 10/11
|
|
|
Change in
accounting
policy
IAS 19
|
|
|
Q1 2012
(restated)
|
|
EUR millions
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash flow from operating activities
|
|
|
(732
|
)
|
|
|
39
|
|
|
|
-
|
|
|
|
(693
|
)
|
Cash flow from investing activities
|
|
|
(31
|
)
|
|
|
4
|
|
|
|
-
|
|
|
|
(27
|
)
|
Cash flow from financing activities
|
|
|
1,523
|
|
|
|
(16
|
)
|
|
|
-
|
|
|
|
1,507
|
|
Net increase / (decrease) in cash and cash equivalents
|
|
|
760
|
|
|
|
27
|
|
|
|
-
|
|
|
|
787
|
|
Net cash and cash equivalents at January 1
|
|
|
7,826
|
|
|
|
(109
|
)
|
|
|
-
|
|
|
|
7,717
|
|
Effects of changes in foreign exchange rates
|
|
|
(17
|
)
|
|
|
2
|
|
|
|
-
|
|
|
|
(15
|
)
|
Net cash and
cash equivalents at end of period
|
|
|
8,569
|
|
|
|
(80
|
)
|
|
|
-
|
|
|
|
8,489
|
|
|
|
|
|
|
|
|
Mar. 31,
2012
(previously
reported)
|
|
|
Change in
accounting
policy
IFRS 10/11
|
|
|
Change in
accounting
policy
IAS 19
|
|
|
Mar. 31,
2012
(restated)
|
|
|
|
|
|
|
Cash and cash equivalents
|
|
|
8,671
|
|
|
|
(80
|
)
|
|
|
-
|
|
|
|
8,591
|
|
Bank overdrafts
|
|
|
(102
|
)
|
|
|
-
|
|
|
|
-
|
|
|
|
(102
|
)
|
Net cash and
cash equivalents
|
|
|
8,569
|
|
|
|
(80
|
)
|
|
|
-
|
|
|
|
8,489
|
|
3. Segment information
3.1 Income statement
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
EUR millions
|
|
Americas
|
|
|
The
Netherlands
|
|
|
United
Kingdom
|
|
|
New
Markets
|
|
|
Holding and
other
activities
|
|
|
Eliminations
|
|
|
Segment
Total
|
|
|
Joint
ventures and
associates
eliminations
|
|
|
Consolidated
|
|
Three months ended March 31,
2013
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Underlying earnings before tax
geographically
|
|
|
312
|
|
|
|
85
|
|
|
|
24
|
|
|
|
62
|
|
|
|
(38
|
)
|
|
|
-
|
|
|
|
445
|
|
|
|
(19
|
)
|
|
|
426
|
|
Fair value items
|
|
|
(232
|
)
|
|
|
(73
|
)
|
|
|
(3
|
)
|
|
|
(3
|
)
|
|
|
25
|
|
|
|
-
|
|
|
|
(286
|
)
|
|
|
16
|
|
|
|
(270
|
)
|
Realized gains / (losses) on
investments
|
|
|
47
|
|
|
|
63
|
|
|
|
1
|
|
|
|
2
|
|
|
|
-
|
|
|
|
-
|
|
|
|
113
|
|
|
|
-
|
|
|
|
113
|
|
Impairment charges
|
|
|
(15
|
)
|
|
|
(8
|
)
|
|
|
-
|
|
|
|
(10
|
)
|
|
|
-
|
|
|
|
-
|
|
|
|
(33
|
)
|
|
|
-
|
|
|
|
(33
|
)
|
Impairment reversals
|
|
|
16
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
16
|
|
|
|
-
|
|
|
|
16
|
|
Other income / (charges)
|
|
|
(5
|
)
|
|
|
-
|
|
|
|
5
|
|
|
|
(4
|
)
|
|
|
-
|
|
|
|
-
|
|
|
|
(4
|
)
|
|
|
-
|
|
|
|
(4
|
)
|
Run-off
businesses
|
|
|
(14
|
)
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
(14
|
)
|
|
|
-
|
|
|
|
(14
|
)
|
Income before tax
|
|
|
109
|
|
|
|
67
|
|
|
|
27
|
|
|
|
47
|
|
|
|
(13
|
)
|
|
|
-
|
|
|
|
237
|
|
|
|
(3
|
)
|
|
|
234
|
|
Income tax
(expense) / benefit
|
|
|
-
|
|
|
|
(8
|
)
|
|
|
(9
|
)
|
|
|
(17
|
)
|
|
|
1
|
|
|
|
-
|
|
|
|
(33
|
)
|
|
|
3
|
|
|
|
(30
|
)
|
Net
income
|
|
|
109
|
|
|
|
59
|
|
|
|
18
|
|
|
|
30
|
|
|
|
(12
|
)
|
|
|
-
|
|
|
|
204
|
|
|
|
-
|
|
|
|
204
|
|
Inter-segment underlying
earnings
|
|
|
(46
|
)
|
|
|
(14
|
)
|
|
|
(14
|
)
|
|
|
67
|
|
|
|
7
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Revenues
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Life insurance gross premiums
|
|
|
1,545
|
|
|
|
2,015
|
|
|
|
1,732
|
|
|
|
350
|
|
|
|
-
|
|
|
|
(19
|
)
|
|
|
5,623
|
|
|
|
(142
|
)
|
|
|
5,481
|
|
Accident and health insurance
|
|
|
444
|
|
|
|
123
|
|
|
|
-
|
|
|
|
58
|
|
|
|
2
|
|
|
|
(2
|
)
|
|
|
625
|
|
|
|
(7
|
)
|
|
|
618
|
|
General
insurance
|
|
|
-
|
|
|
|
128
|
|
|
|
-
|
|
|
|
40
|
|
|
|
-
|
|
|
|
-
|
|
|
|
168
|
|
|
|
-
|
|
|
|
168
|
|
Total gross premiums
|
|
|
1,989
|
|
|
|
2,266
|
|
|
|
1,732
|
|
|
|
448
|
|
|
|
2
|
|
|
|
(21
|
)
|
|
|
6,416
|
|
|
|
(149
|
)
|
|
|
6,267
|
|
Investment income
|
|
|
841
|
|
|
|
548
|
|
|
|
580
|
|
|
|
65
|
|
|
|
84
|
|
|
|
(83
|
)
|
|
|
2,035
|
|
|
|
(22
|
)
|
|
|
2,013
|
|
Fee and commission income
|
|
|
297
|
|
|
|
82
|
|
|
|
26
|
|
|
|
134
|
|
|
|
-
|
|
|
|
(59
|
)
|
|
|
480
|
|
|
|
(14
|
)
|
|
|
466
|
|
Other
revenues
|
|
|
1
|
|
|
|
-
|
|
|
|
-
|
|
|
|
1
|
|
|
|
1
|
|
|
|
-
|
|
|
|
3
|
|
|
|
(1
|
)
|
|
|
2
|
|
Total
revenues
|
|
|
3,128
|
|
|
|
2,896
|
|
|
|
2,338
|
|
|
|
648
|
|
|
|
87
|
|
|
|
(163
|
)
|
|
|
8,934
|
|
|
|
(186
|
)
|
|
|
8,748
|
|
Inter-segment
revenues
|
|
|
5
|
|
|
|
-
|
|
|
|
-
|
|
|
|
73
|
|
|
|
85
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
EUR millions
|
|
Americas
|
|
|
The
Netherlands
|
|
|
United
Kingdom
|
|
|
New
Markets
|
|
|
Holding and
other
activities
|
|
|
Eliminations
|
|
|
Segment
Total
|
|
|
Joint
ventures and
associates
eliminations
|
|
|
Consolidated
|
|
Three months ended March 31,
2012
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Underlying earnings before tax
geographically
|
|
|
303
|
|
|
|
81
|
|
|
|
30
|
|
|
|
88
|
|
|
|
(61
|
)
|
|
|
(2
|
)
|
|
|
439
|
|
|
|
(15
|
)
|
|
|
424
|
|
Fair value items
|
|
|
64
|
|
|
|
34
|
|
|
|
(2
|
)
|
|
|
7
|
|
|
|
45
|
|
|
|
-
|
|
|
|
148
|
|
|
|
11
|
|
|
|
159
|
|
Realized gains / (losses) on
investments
|
|
|
9
|
|
|
|
34
|
|
|
|
-
|
|
|
|
2
|
|
|
|
-
|
|
|
|
-
|
|
|
|
45
|
|
|
|
-
|
|
|
|
45
|
|
Impairment charges
|
|
|
(36
|
)
|
|
|
(3
|
)
|
|
|
-
|
|
|
|
(4
|
)
|
|
|
(4
|
)
|
|
|
-
|
|
|
|
(47
|
)
|
|
|
-
|
|
|
|
(47
|
)
|
Impairment reversals
|
|
|
6
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
6
|
|
|
|
-
|
|
|
|
6
|
|
Other income / (charges)
|
|
|
(1
|
)
|
|
|
(3
|
)
|
|
|
6
|
|
|
|
(18
|
)
|
|
|
(1
|
)
|
|
|
-
|
|
|
|
(17
|
)
|
|
|
-
|
|
|
|
(17
|
)
|
Run-off
businesses
|
|
|
(2
|
)
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
(2
|
)
|
|
|
-
|
|
|
|
(2
|
)
|
Income before tax
|
|
|
343
|
|
|
|
143
|
|
|
|
34
|
|
|
|
75
|
|
|
|
(21
|
)
|
|
|
(2
|
)
|
|
|
572
|
|
|
|
(4
|
)
|
|
|
568
|
|
Income tax
(expense) / benefit
|
|
|
(57
|
)
|
|
|
(6
|
)
|
|
|
13
|
|
|
|
(27
|
)
|
|
|
30
|
|
|
|
-
|
|
|
|
(47
|
)
|
|
|
4
|
|
|
|
(43
|
)
|
Net
income
|
|
|
286
|
|
|
|
137
|
|
|
|
47
|
|
|
|
48
|
|
|
|
9
|
|
|
|
(2
|
)
|
|
|
525
|
|
|
|
-
|
|
|
|
525
|
|
Inter-segment underlying
earnings
|
|
|
(46
|
)
|
|
|
(12
|
)
|
|
|
(16
|
)
|
|
|
71
|
|
|
|
3
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Revenues
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Life insurance gross premiums
|
|
|
1,581
|
|
|
|
1,772
|
|
|
|
1,415
|
|
|
|
408
|
|
|
|
-
|
|
|
|
(18
|
)
|
|
|
5,158
|
|
|
|
(247
|
)
|
|
|
4,911
|
|
Accident and health insurance
|
|
|
444
|
|
|
|
109
|
|
|
|
-
|
|
|
|
62
|
|
|
|
1
|
|
|
|
(1
|
)
|
|
|
615
|
|
|
|
(7
|
)
|
|
|
608
|
|
General
insurance
|
|
|
-
|
|
|
|
134
|
|
|
|
-
|
|
|
|
37
|
|
|
|
-
|
|
|
|
-
|
|
|
|
171
|
|
|
|
-
|
|
|
|
171
|
|
Total gross premiums
|
|
|
2,025
|
|
|
|
2,015
|
|
|
|
1,415
|
|
|
|
507
|
|
|
|
1
|
|
|
|
(19
|
)
|
|
|
5,944
|
|
|
|
(254
|
)
|
|
|
5,690
|
|
Investment income
|
|
|
890
|
|
|
|
569
|
|
|
|
562
|
|
|
|
86
|
|
|
|
89
|
|
|
|
(87
|
)
|
|
|
2,109
|
|
|
|
(49
|
)
|
|
|
2,060
|
|
Fee and commission income
|
|
|
285
|
|
|
|
86
|
|
|
|
31
|
|
|
|
128
|
|
|
|
-
|
|
|
|
(65
|
)
|
|
|
465
|
|
|
|
(10
|
)
|
|
|
455
|
|
Other
revenues
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
1
|
|
|
|
1
|
|
|
|
-
|
|
|
|
2
|
|
|
|
-
|
|
|
|
2
|
|
Total
revenues
|
|
|
3,200
|
|
|
|
2,670
|
|
|
|
2,008
|
|
|
|
722
|
|
|
|
91
|
|
|
|
(171
|
)
|
|
|
8,520
|
|
|
|
(313
|
)
|
|
|
8,207
|
|
Inter-segment
revenues
|
|
|
7
|
|
|
|
-
|
|
|
|
1
|
|
|
|
76
|
|
|
|
87
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Non-IFRS measures
For
segment reporting purposes the following non-IFRS financial measures are included: underlying earnings before tax, income tax and income before tax. These non-IFRS measures are calculated by consolidating on a proportionate basis Aegons joint
ventures and associated companies. Aegon believes that its non-IFRS measures provide meaningful information about the underlying results of Aegons business, including insight into the financial measures that Aegons senior management
uses in managing the business.
Among other things, Aegons senior management is compensated based in part on Aegons results against
targets using the non-IFRS measures presented here. While many other insurers in Aegons peer group present substantially similar non-IFRS measures, the non-IFRS measures presented in this document may nevertheless differ from the non-IFRS
measures presented by other insurers. There is no standardized meaning to these measures under IFRS or any other recognized set of accounting standards. Readers are cautioned to consider carefully the different ways in which Aegon and its peers
present similar information before comparing them.
Aegon believes the non-IFRS measures shown herein, when read together with Aegons reported
IFRS financial statements, provide meaningful supplemental information for the investing public to evaluate Aegons business after eliminating the impact of current IFRS accounting policies for financial instruments and insurance contracts,
which embed a number of accounting policies alternatives that companies may select in presenting their results (i.e. companies can use different local GAAPs to measure the insurance contract liability) and that can make the comparability from period
to period difficult.
The reconciliation from underlying earnings before tax to income before tax, being the most comparable IFRS measure, is presented
in the tables in this note.
Underlying earnings
Certain assets held by Aegon Americas, Aegon the Netherlands and Aegon United Kingdom are carried at fair value and managed on a total return basis, with no
offsetting changes in the valuation of related liabilities. These include assets such as investments in hedge funds, private equities, real estate (limited partnerships), convertible bonds and structured products. Underlying earnings exclude any
over- or underperformance compared to managements long-term expected return on assets.
Based on current holdings and asset returns, the long-term
expected return on an annual basis is 8-10%, depending on asset class, including cash income and market value changes. The expected earnings from these asset classes are net of deferred policy acquisition costs (DPAC) where applicable.
In addition, certain products offered by Aegon Americas contain guarantees and are reported on a fair value basis, including the segregated funds offered by Aegon
Canada and the total return annuities and guarantees on variable annuities of Aegon USA. The earnings on these products are impacted by movements in equity markets and risk-free interest rates. Short-term developments in the financial markets may
therefore cause volatility in earnings. Included in underlying earnings is a long-term expected return on these products and excluded is any over- or underperformance compared to managements expected return. The fair value movements of certain
guarantees and the fair value change of derivatives that hedge certain risks on these guarantees of Aegon the Netherlands and Variable Annuities Europe (included in New Markets) are excluded from underlying earnings, and the long-term expected
return for these guarantees is set at zero.
Holding and other activities include certain issued bonds that are held at fair value through profit or
loss (FVTPL). The interest rate risk on these bonds is hedged using swaps. The fair value movement resulting from changes in Aegons credit spread used in the valuation of these bonds are excluded from underlying earnings and reported under
fair value items.
Fair value items
Fair value
items include the over- or underperformance of investments and guarantees held at fair value for which the expected long-term return is included in underlying earnings. Changes to these long-term return assumptions are also included in the fair
value items.
In addition, hedge ineffectiveness on hedge transactions, fair value changes on economic hedges without natural offset in earnings and for
which no hedge accounting is applied and fair value movements on real estate are included under fair value items.
Realized gains or losses on investments
Includes realized gains and losses on available-for-sale investments, mortgage loans and other loan portfolios.
Impairment charges / reversals
Includes impairments and
reversals on available-for-sale debt securities and impairments on shares including the effect of deferred policyholder acquisition costs, mortgage loans and loan portfolios on amortized cost and associates respectively.
Other income or charges
Other income or charges is used to
report any items which cannot be directly allocated to a specific line of business. Also items that are outside the normal course of business are reported under this heading.
Other charges include restructuring charges that are considered other charges for segment reporting purposes because they are outside the normal course of business. In the condensed consolidated income statement,
these charges are included in operating expenses.
Run-off businesses
Includes underlying results of business units where management has decided to exit the market and to run-off the existing block of business. Currently, this line includes the run-off of the institutional
spread-based business, structured settlements blocks of business, Bank-Owned and Corporate-Owned Life Insurance (BOLI/COLI) business and life reinsurance business in the United States. Aegon has other blocks of business for which sales have been
discontinued and of which the earnings are included in underlying earnings.
Share in earnings of joint ventures and associates
Earnings from Aegons joint ventures in Spain, China and Japan and Aegons associates in Spain, India, Brazil and Mexico are reported on an underlying
earnings basis.
3.2 Investments geographically
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
amounts in million EUR (unless otherwise stated)
|
|
Americas
USD
|
|
|
United
Kingdom
GBP
|
|
|
March 31, 2013
|
|
Americas
|
|
|
The
Netherlands
|
|
|
United
Kingdom
|
|
|
New
Markets
|
|
|
Holding
& other
activities
|
|
|
Eliminations
|
|
|
Total
EUR
|
|
|
|
|
|
|
|
|
|
Investments
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1,923
|
|
|
|
46
|
|
|
Shares
|
|
|
1,497
|
|
|
|
492
|
|
|
|
55
|
|
|
|
20
|
|
|
|
-
|
|
|
|
(2
|
)
|
|
|
2,062
|
|
|
83,940
|
|
|
|
9,099
|
|
|
Debt securities
|
|
|
65,369
|
|
|
|
19,505
|
|
|
|
10,760
|
|
|
|
2,726
|
|
|
|
-
|
|
|
|
-
|
|
|
|
98,360
|
|
|
11,534
|
|
|
|
3
|
|
|
Loans
|
|
|
8,982
|
|
|
|
22,705
|
|
|
|
4
|
|
|
|
538
|
|
|
|
-
|
|
|
|
-
|
|
|
|
32,229
|
|
|
13,045
|
|
|
|
155
|
|
|
Other financial assets
|
|
|
10,159
|
|
|
|
295
|
|
|
|
183
|
|
|
|
23
|
|
|
|
757
|
|
|
|
-
|
|
|
|
11,417
|
|
|
1,036
|
|
|
|
-
|
|
|
Investments in real estate
|
|
|
807
|
|
|
|
842
|
|
|
|
-
|
|
|
|
1
|
|
|
|
-
|
|
|
|
-
|
|
|
|
1,650
|
|
|
111,478
|
|
|
|
9,303
|
|
|
Investments general account
|
|
|
86,814
|
|
|
|
43,839
|
|
|
|
11,002
|
|
|
|
3,308
|
|
|
|
757
|
|
|
|
(2
|
)
|
|
|
145,718
|
|
|
1,898
|
|
|
|
13,315
|
|
|
Shares
|
|
|
1,478
|
|
|
|
8,730
|
|
|
|
15,746
|
|
|
|
65
|
|
|
|
-
|
|
|
|
(6
|
)
|
|
|
26,013
|
|
|
6,842
|
|
|
|
10,313
|
|
|
Debt securities
|
|
|
5,328
|
|
|
|
15,950
|
|
|
|
12,195
|
|
|
|
152
|
|
|
|
-
|
|
|
|
-
|
|
|
|
33,625
|
|
|
82,801
|
|
|
|
21,078
|
|
|
Unconsolidated investment funds
|
|
|
64,482
|
|
|
|
-
|
|
|
|
24,927
|
|
|
|
5,702
|
|
|
|
-
|
|
|
|
-
|
|
|
|
95,111
|
|
|
345
|
|
|
|
2,636
|
|
|
Other financial assets
|
|
|
269
|
|
|
|
412
|
|
|
|
3,118
|
|
|
|
17
|
|
|
|
-
|
|
|
|
-
|
|
|
|
3,816
|
|
|
-
|
|
|
|
844
|
|
|
Investments in real estate
|
|
|
-
|
|
|
|
-
|
|
|
|
998
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
998
|
|
|
91,886
|
|
|
|
48,186
|
|
|
Investments for account of policyholders
|
|
|
71,557
|
|
|
|
25,092
|
|
|
|
56,984
|
|
|
|
5,936
|
|
|
|
-
|
|
|
|
(6
|
)
|
|
|
159,563
|
|
|
|
|
|
|
|
|
|
|
|
|
203,364
|
|
|
|
57,489
|
|
|
Investments on balance sheet
|
|
|
158,371
|
|
|
|
68,931
|
|
|
|
67,986
|
|
|
|
9,244
|
|
|
|
757
|
|
|
|
(8
|
)
|
|
|
305,281
|
|
|
139,658
|
|
|
|
54
|
|
|
Off balance sheet investments third parties
|
|
|
108,759
|
|
|
|
1,031
|
|
|
|
64
|
|
|
|
61,101
|
|
|
|
-
|
|
|
|
-
|
|
|
|
170,955
|
|
|
343,022
|
|
|
|
57,543
|
|
|
Total revenue generating investments
|
|
|
267,130
|
|
|
|
69,962
|
|
|
|
68,050
|
|
|
|
70,345
|
|
|
|
757
|
|
|
|
(8
|
)
|
|
|
476,236
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Investments
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
92,910
|
|
|
|
9,258
|
|
|
Available-for-sale
|
|
|
72,354
|
|
|
|
20,020
|
|
|
|
10,949
|
|
|
|
2,735
|
|
|
|
17
|
|
|
|
-
|
|
|
|
106,075
|
|
|
11,534
|
|
|
|
3
|
|
|
Loans
|
|
|
8,982
|
|
|
|
22,705
|
|
|
|
4
|
|
|
|
538
|
|
|
|
-
|
|
|
|
-
|
|
|
|
32,229
|
|
|
97,884
|
|
|
|
47,384
|
|
|
Financial assets at fair value through profit or loss
|
|
|
76,228
|
|
|
|
25,364
|
|
|
|
56,035
|
|
|
|
5,970
|
|
|
|
740
|
|
|
|
(8
|
)
|
|
|
164,329
|
|
|
1,036
|
|
|
|
844
|
|
|
Investments in real estate
|
|
|
807
|
|
|
|
842
|
|
|
|
998
|
|
|
|
1
|
|
|
|
-
|
|
|
|
-
|
|
|
|
2,648
|
|
|
203,364
|
|
|
|
57,489
|
|
|
Total investments on balance sheet
|
|
|
158,371
|
|
|
|
68,931
|
|
|
|
67,986
|
|
|
|
9,244
|
|
|
|
757
|
|
|
|
(8
|
)
|
|
|
305,281
|
|
|
|
|
|
|
|
|
|
|
|
|
-
|
|
|
|
-
|
|
|
Investments in joint ventures
|
|
|
-
|
|
|
|
842
|
|
|
|
-
|
|
|
|
727
|
|
|
|
-
|
|
|
|
-
|
|
|
|
1,569
|
|
|
123
|
|
|
|
6
|
|
|
Investments in associates
|
|
|
96
|
|
|
|
21
|
|
|
|
8
|
|
|
|
662
|
|
|
|
4
|
|
|
|
-
|
|
|
|
791
|
|
|
33,231
|
|
|
|
5,261
|
|
|
Other assets
|
|
|
25,817
|
|
|
|
25,045
|
|
|
|
6,214
|
|
|
|
3,332
|
|
|
|
37,537
|
|
|
|
(35,907
|
)
|
|
|
62,038
|
|
|
236,718
|
|
|
|
62,756
|
|
|
Consolidated total assets
|
|
|
184,284
|
|
|
|
94,839
|
|
|
|
74,208
|
|
|
|
13,965
|
|
|
|
38,298
|
|
|
|
(35,915
|
)
|
|
|
369,679
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
amounts in million EUR (unless otherwise stated)
|
|
Americas
USD
|
|
|
United
Kingdom
GBP
|
|
|
December 31, 2012
|
|
Americas
|
|
|
The
Netherlands
|
|
|
United
Kingdom
|
|
|
New
Markets
|
|
|
Holding
& other
activities
|
|
|
Eliminations
|
|
|
Total
EUR
|
|
|
|
|
|
|
|
|
|
Investments
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1,833
|
|
|
|
42
|
|
|
Shares
|
|
|
1,390
|
|
|
|
412
|
|
|
|
51
|
|
|
|
16
|
|
|
|
-
|
|
|
|
(2
|
)
|
|
|
1,867
|
|
|
83,964
|
|
|
|
8,975
|
|
|
Debt securities
|
|
|
63,686
|
|
|
|
19,256
|
|
|
|
11,066
|
|
|
|
2,817
|
|
|
|
-
|
|
|
|
-
|
|
|
|
96,825
|
|
|
11,748
|
|
|
|
4
|
|
|
Loans
|
|
|
8,910
|
|
|
|
22,245
|
|
|
|
5
|
|
|
|
552
|
|
|
|
-
|
|
|
|
-
|
|
|
|
31,712
|
|
|
15,434
|
|
|
|
175
|
|
|
Other financial assets
|
|
|
11,707
|
|
|
|
286
|
|
|
|
216
|
|
|
|
22
|
|
|
|
759
|
|
|
|
-
|
|
|
|
12,990
|
|
|
1,009
|
|
|
|
-
|
|
|
Investments in real estate
|
|
|
766
|
|
|
|
860
|
|
|
|
-
|
|
|
|
1
|
|
|
|
-
|
|
|
|
-
|
|
|
|
1,627
|
|
|
113,988
|
|
|
|
9,196
|
|
|
Investments general account
|
|
|
86,459
|
|
|
|
43,059
|
|
|
|
11,338
|
|
|
|
3,408
|
|
|
|
759
|
|
|
|
(2
|
)
|
|
|
145,021
|
|
|
1,956
|
|
|
|
12,107
|
|
|
Shares
|
|
|
1,484
|
|
|
|
8,406
|
|
|
|
14,927
|
|
|
|
63
|
|
|
|
-
|
|
|
|
(6
|
)
|
|
|
24,874
|
|
|
6,988
|
|
|
|
10,508
|
|
|
Debt securities
|
|
|
5,300
|
|
|
|
16,266
|
|
|
|
12,954
|
|
|
|
162
|
|
|
|
-
|
|
|
|
-
|
|
|
|
34,682
|
|
|
77,824
|
|
|
|
19,136
|
|
|
Unconsolidated investment funds
|
|
|
59,029
|
|
|
|
-
|
|
|
|
23,593
|
|
|
|
5,778
|
|
|
|
-
|
|
|
|
-
|
|
|
|
88,400
|
|
|
207
|
|
|
|
2,761
|
|
|
Other financial assets
|
|
|
157
|
|
|
|
422
|
|
|
|
3,404
|
|
|
|
21
|
|
|
|
-
|
|
|
|
-
|
|
|
|
4,004
|
|
|
-
|
|
|
|
817
|
|
|
Investments in real estate
|
|
|
-
|
|
|
|
-
|
|
|
|
1,008
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
1,008
|
|
|
86,975
|
|
|
|
45,329
|
|
|
Investments for account of policyholders
|
|
|
65,970
|
|
|
|
25,094
|
|
|
|
55,886
|
|
|
|
6,024
|
|
|
|
-
|
|
|
|
(6
|
)
|
|
|
152,968
|
|
|
|
|
|
|
|
|
|
|
|
|
200,963
|
|
|
|
54,525
|
|
|
Investments on balance sheet
|
|
|
152,429
|
|
|
|
68,153
|
|
|
|
67,224
|
|
|
|
9,432
|
|
|
|
759
|
|
|
|
(8
|
)
|
|
|
297,989
|
|
|
132,796
|
|
|
|
8
|
|
|
Off balance sheet investments third parties
|
|
|
100,725
|
|
|
|
1,052
|
|
|
|
10
|
|
|
|
59,301
|
|
|
|
-
|
|
|
|
-
|
|
|
|
161,088
|
|
|
333,759
|
|
|
|
54,533
|
|
|
Total revenue generating investments
|
|
|
253,154
|
|
|
|
69,205
|
|
|
|
67,234
|
|
|
|
68,733
|
|
|
|
759
|
|
|
|
(8
|
)
|
|
|
459,077
|
|
|
|
|
|
|
|
|
|
Investments
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
95,282
|
|
|
|
9,155
|
|
|
Available-for-sale
|
|
|
72,271
|
|
|
|
19,717
|
|
|
|
11,286
|
|
|
|
2,826
|
|
|
|
19
|
|
|
|
-
|
|
|
|
106,119
|
|
|
11,748
|
|
|
|
4
|
|
|
Loans
|
|
|
8,910
|
|
|
|
22,245
|
|
|
|
5
|
|
|
|
552
|
|
|
|
-
|
|
|
|
-
|
|
|
|
31,712
|
|
|
92,924
|
|
|
|
44,549
|
|
|
Financial assets at fair value through profit or loss
|
|
|
70,482
|
|
|
|
25,331
|
|
|
|
54,925
|
|
|
|
6,053
|
|
|
|
740
|
|
|
|
(8
|
)
|
|
|
157,523
|
|
|
1,009
|
|
|
|
817
|
|
|
Investments in real estate
|
|
|
766
|
|
|
|
860
|
|
|
|
1,008
|
|
|
|
1
|
|
|
|
-
|
|
|
|
-
|
|
|
|
2,635
|
|
|
200,963
|
|
|
|
54,525
|
|
|
Total investments on balance sheet
|
|
|
152,429
|
|
|
|
68,153
|
|
|
|
67,224
|
|
|
|
9,432
|
|
|
|
759
|
|
|
|
(8
|
)
|
|
|
297,989
|
|
|
|
|
|
|
|
|
|
|
|
|
-
|
|
|
|
-
|
|
|
Investments in joint ventures
|
|
|
-
|
|
|
|
854
|
|
|
|
-
|
|
|
|
714
|
|
|
|
-
|
|
|
|
-
|
|
|
|
1,568
|
|
|
119
|
|
|
|
6
|
|
|
Investments in associates
|
|
|
90
|
|
|
|
21
|
|
|
|
8
|
|
|
|
648
|
|
|
|
4
|
|
|
|
-
|
|
|
|
771
|
|
|
33,852
|
|
|
|
5,104
|
|
|
Other assets
|
|
|
25,586
|
|
|
|
27,508
|
|
|
|
6,284
|
|
|
|
3,318
|
|
|
|
37,926
|
|
|
|
(36,066
|
)
|
|
|
64,556
|
|
|
234,934
|
|
|
|
59,635
|
|
|
Consolidated total assets
|
|
|
178,105
|
|
|
|
96,536
|
|
|
|
73,516
|
|
|
|
14,112
|
|
|
|
38,689
|
|
|
|
(36,074
|
)
|
|
|
364,884
|
|
Amounts included in the tables on investments geographically are presented on an IFRS-basis and include the reclassifications
following the change in accounting policies as included in notes 2.1 to 2.4.
4. Premium income and premium to reinsurers
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
EUR millions
|
|
|
Q1 2013
|
|
|
|
Q1 2012
|
|
|
|
|
Gross
|
|
|
|
|
|
|
|
|
Life
|
|
|
5,481
|
|
|
|
4,911
|
|
Non-Life
|
|
|
786
|
|
|
|
779
|
|
Total
|
|
|
6,267
|
|
|
|
5,690
|
|
|
|
|
Reinsurance
|
|
|
|
|
|
|
|
|
Life
|
|
|
671
|
|
|
|
820
|
|
Non-Life
|
|
|
90
|
|
|
|
96
|
|
Total
|
|
|
761
|
|
|
|
916
|
|
5. Investment income
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
EUR millions
|
|
|
Q1 2013
|
|
|
|
Q1 2012
|
|
|
|
|
Interest income
|
|
|
1,691
|
|
|
|
1,805
|
|
Dividend income
|
|
|
292
|
|
|
|
225
|
|
Rental income
|
|
|
30
|
|
|
|
30
|
|
Total investment income
|
|
|
2,013
|
|
|
|
2,060
|
|
|
|
|
Investment income related to general account
|
|
|
1,384
|
|
|
|
1,447
|
|
Investment income for account of
policyholders
|
|
|
629
|
|
|
|
613
|
|
Total
|
|
|
2,013
|
|
|
|
2,060
|
|
6. Results from financial transactions
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
EUR millions
|
|
|
Q1 2013
|
|
|
|
Q1 2012
|
|
|
|
|
Net fair value change of general account financial investments at FVTPL other than
derivatives
|
|
|
144
|
|
|
|
265
|
|
Realized gains and (losses) on financial investments
|
|
|
113
|
|
|
|
55
|
|
Gains and (losses) on investments in real estate
|
|
|
(15
|
)
|
|
|
(14
|
)
|
Net fair value change of derivatives
|
|
|
(265
|
)
|
|
|
120
|
|
Net fair value change on for account of policyholder financial assets at
FVTPL
|
|
|
7,743
|
|
|
|
7,152
|
|
Net fair value change on investments in real estate for account of
policyholders
|
|
|
(10
|
)
|
|
|
(8
|
)
|
Net foreign currency gains and (losses)
|
|
|
2
|
|
|
|
10
|
|
Net fair value change on borrowings and other
financial liabilities
|
|
|
19
|
|
|
|
(24
|
)
|
Total
|
|
|
7,731
|
|
|
|
7,556
|
|
Net fair value changes on for account of policyholder financial assets at fair value through profit or loss are offset by amounts
in Claims and benefits reported in the Benefits and expenses line (note 8).
7. Other income
Other income in 2013 reflects the recapture of certain reinsurance contracts.
8. Benefits and expenses
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
EUR millions
|
|
|
Q1 2013
|
|
|
|
Q1 2012
|
|
|
|
|
Claims and benefits
|
|
|
16,213
|
|
|
|
15,306
|
|
Employee expenses
|
|
|
512
|
|
|
|
483
|
|
Administration expenses
|
|
|
263
|
|
|
|
252
|
|
Deferred expenses
|
|
|
(365
|
)
|
|
|
(361
|
)
|
Amortization charges
|
|
|
286
|
|
|
|
264
|
|
Total
|
|
|
16,909
|
|
|
|
15,944
|
|
Claims and benefits reflects the claims and benefits paid to policyholders, including claims and benefits in excess of account
value for products for which deposit accounting is applied and the change in valuation of liabilities for insurance and investment contracts. In addition, Claims and benefits includes commissions and expenses, as well as premium paid to reinsurers.
Claims and benefits fluctuates mainly as a result of changes in technical provisions resulting from fair value changes on for account of policyholder financial assets included in Results from financial transactions (note 6).
9. Impairment charges / (reversals)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
EUR millions
|
|
|
Q1 2013
|
|
|
|
Q1 2012
|
|
|
|
|
Impairment charges / (reversals) comprise:
|
|
|
|
|
|
|
|
|
Impairment charges on financial assets, excluding receivables
1
|
|
|
40
|
|
|
|
50
|
|
Impairment reversals on financial assets, excluding receivables
1
|
|
|
(16
|
)
|
|
|
(6
|
)
|
Impairment charges / (reversals) on non-financial
assets and receivables
|
|
|
1
|
|
|
|
2
|
|
Total
|
|
|
25
|
|
|
|
46
|
|
|
|
|
Impairment charges on financial assets, excluding receivables,
from:
|
|
|
|
|
|
|
|
|
Shares
|
|
|
-
|
|
|
|
4
|
|
Debt securities and money market instruments
|
|
|
13
|
|
|
|
31
|
|
Loans
|
|
|
27
|
|
|
|
14
|
|
Other
|
|
|
-
|
|
|
|
1
|
|
Total
|
|
|
40
|
|
|
|
50
|
|
|
|
|
Impairment reversals on financial assets, excluding receivables,
from:
|
|
|
|
|
|
|
|
|
Debt securities and money market instruments
|
|
|
(14
|
)
|
|
|
(1
|
)
|
Loans
|
|
|
(2
|
)
|
|
|
(5
|
)
|
Total
|
|
|
(16
|
)
|
|
|
(6
|
)
|
1
Impairment charges / (reversals) on financial assets, excluding receivables, are excluded from underlying earnings before tax for
segment reporting (refer to note 3).
10. Other charges
Other charges in 2013 mainly includes EUR 81 million related to a further increase in reserves in connection with the companys use of the Social Security Administrations death master-file in the
United States.
Other charges in 2012 mainly includes EUR 16 million related to the Hungarian bank tax. Due to regulation changes in Hungary, the
bank tax has been replaced by a recurring insurance tax for which charges are recognized in operating expenses effective January 1, 2013.
11. Intangible assets
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
EUR millions
|
|
|
Mar. 31, 2013
|
|
|
|
Dec. 31, 2012
|
|
|
|
|
Goodwill
|
|
|
277
|
|
|
|
266
|
|
VOBA
|
|
|
1,789
|
|
|
|
1,777
|
|
Future servicing rights
|
|
|
384
|
|
|
|
383
|
|
Software
|
|
|
48
|
|
|
|
50
|
|
Other
|
|
|
8
|
|
|
|
9
|
|
Total intangible assets
|
|
|
2,506
|
|
|
|
2,485
|
|
The increase in goodwill mainly reflects the acquisition of 100% of Fidem Life, a life insurance company in Ukraine. The increase
in value of business acquired (VOBA) is mainly attributable to currency translation adjustments partly offset by the net impact of regular amortization and shadow accounting.
12. Investments
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
EUR millions
|
|
|
Mar. 31, 2013
|
|
|
|
Dec. 31, 2012
|
|
|
|
|
Available-for-sale (AFS)
|
|
|
106,075
|
|
|
|
106,119
|
|
Loans
|
|
|
32,229
|
|
|
|
31,712
|
|
Financial assets at fair value through profit or
loss (FVTPL)
|
|
|
5,764
|
|
|
|
5,563
|
|
Financial assets, excluding derivatives
|
|
|
144,068
|
|
|
|
143,394
|
|
Investments in real estate
|
|
|
1,650
|
|
|
|
1,627
|
|
Total investments for general account
|
|
|
145,718
|
|
|
|
145,021
|
|
|
|
|
|
|
Total financial assets, excluding derivatives
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
AFS
|
|
|
|
FVTPL
|
|
|
|
Loans
|
|
|
|
Total
|
|
|
|
|
|
|
Shares
|
|
|
874
|
|
|
|
1,188
|
|
|
|
-
|
|
|
|
2,062
|
|
Debt securities
|
|
|
96,927
|
|
|
|
1,433
|
|
|
|
-
|
|
|
|
98,360
|
|
Money market and other short-term investments
|
|
|
7,065
|
|
|
|
1,107
|
|
|
|
-
|
|
|
|
8,172
|
|
Mortgages
|
|
|
-
|
|
|
|
-
|
|
|
|
28,851
|
|
|
|
28,851
|
|
Private loans
|
|
|
-
|
|
|
|
-
|
|
|
|
1,005
|
|
|
|
1,005
|
|
Deposits with financial institutions
|
|
|
-
|
|
|
|
-
|
|
|
|
84
|
|
|
|
84
|
|
Policy loans
|
|
|
-
|
|
|
|
-
|
|
|
|
2,143
|
|
|
|
2,143
|
|
Other
|
|
|
1,209
|
|
|
|
2,036
|
|
|
|
146
|
|
|
|
3,391
|
|
March 31, 2013
|
|
|
106,075
|
|
|
|
5,764
|
|
|
|
32,229
|
|
|
|
144,068
|
|
|
|
|
|
|
|
|
|
AFS
|
|
|
|
FVTPL
|
|
|
|
Loans
|
|
|
|
Total
|
|
|
|
|
|
|
Shares
|
|
|
824
|
|
|
|
1,043
|
|
|
|
-
|
|
|
|
1,867
|
|
Debt securities
|
|
|
95,394
|
|
|
|
1,431
|
|
|
|
-
|
|
|
|
96,825
|
|
Money market and other short-term investments
|
|
|
8,687
|
|
|
|
1,084
|
|
|
|
-
|
|
|
|
9,771
|
|
Mortgages
|
|
|
-
|
|
|
|
-
|
|
|
|
28,350
|
|
|
|
28,350
|
|
Private loans
|
|
|
-
|
|
|
|
-
|
|
|
|
1,012
|
|
|
|
1,012
|
|
Deposits with financial institutions
|
|
|
-
|
|
|
|
-
|
|
|
|
96
|
|
|
|
96
|
|
Policy loans
|
|
|
-
|
|
|
|
-
|
|
|
|
2,103
|
|
|
|
2,103
|
|
Other
|
|
|
1,214
|
|
|
|
2,005
|
|
|
|
151
|
|
|
|
3,370
|
|
December 31, 2012
|
|
|
106,119
|
|
|
|
5,563
|
|
|
|
31,712
|
|
|
|
143,394
|
|
European peripheral countries exposure
Aegons exposure to central governments of European peripheral countries Portugal, Italy, Ireland, Greece and Spain amounts to EUR 1,054 million (December 31, 2012: EUR 964 million), which includes
investments held by joint ventures and associates, additional to Aegons direct exposure. EUR 337 million (December 31, 2012: EUR 269 million) relates to Aegons proportionate share in the investments of its associate CAM Aegon
Holding Financiero (Spain).
The following table provides the amortized cost and fair value of Aegons exposure to European peripheral countries.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
EUR millions
Debt security exposure
to:
|
|
|
Mar. 31, 2013
|
|
|
Dec. 31, 2012
|
|
|
|
Central Government
|
|
|
Banks
|
|
|
RMBS
|
|
|
Corporates and other
|
|
|
Total
|
|
|
Total
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Amortized
cost
|
|
|
Fair value
|
|
|
Amortized
cost
|
|
|
Fair value
|
|
|
Amortized
cost
|
|
|
Fair value
|
|
|
Amortized
cost
|
|
|
Fair value
|
|
|
Amortized
cost
|
|
|
Fair value
|
|
|
Amortized
cost
|
|
|
Fair value
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Portugal
|
|
|
2
|
|
|
|
2
|
|
|
|
13
|
|
|
|
9
|
|
|
|
33
|
|
|
|
30
|
|
|
|
54
|
|
|
|
53
|
|
|
|
102
|
|
|
|
94
|
|
|
|
107
|
|
|
|
97
|
|
Italy
|
|
|
46
|
|
|
|
45
|
|
|
|
89
|
|
|
|
88
|
|
|
|
34
|
|
|
|
36
|
|
|
|
596
|
|
|
|
591
|
|
|
|
765
|
|
|
|
760
|
|
|
|
753
|
|
|
|
753
|
|
Ireland
|
|
|
20
|
|
|
|
20
|
|
|
|
-
|
|
|
|
-
|
|
|
|
84
|
|
|
|
72
|
|
|
|
326
|
|
|
|
354
|
|
|
|
430
|
|
|
|
446
|
|
|
|
475
|
|
|
|
484
|
|
Greece
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
3
|
|
|
|
3
|
|
|
|
24
|
|
|
|
25
|
|
|
|
27
|
|
|
|
28
|
|
|
|
27
|
|
|
|
27
|
|
Spain
|
|
|
986
|
|
|
|
986
|
|
|
|
165
|
|
|
|
154
|
|
|
|
653
|
|
|
|
634
|
|
|
|
691
|
|
|
|
717
|
|
|
|
2,495
|
|
|
|
2,491
|
|
|
|
2,488
|
|
|
|
2,426
|
|
Total
|
|
|
1,054
|
|
|
|
1,053
|
|
|
|
267
|
|
|
|
251
|
|
|
|
807
|
|
|
|
775
|
|
|
|
1,691
|
|
|
|
1,740
|
|
|
|
3,819
|
|
|
|
3,819
|
|
|
|
3,850
|
|
|
|
3,787
|
|
13. Investments for account of policyholders
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
EUR millions
|
|
Mar. 31, 2013
|
|
|
Dec. 31, 2012
|
|
Shares
|
|
|
26,013
|
|
|
|
24,874
|
|
Debt securities
|
|
|
33,625
|
|
|
|
34,682
|
|
Money market and short-term investments
|
|
|
1,144
|
|
|
|
1,480
|
|
Deposits with financial institutions
|
|
|
2,250
|
|
|
|
2,087
|
|
Unconsolidated investment funds
|
|
|
95,111
|
|
|
|
88,400
|
|
Other
|
|
|
422
|
|
|
|
437
|
|
Total investments for account of policyholders at fair value through profit or
loss, excluding derivatives
|
|
|
158,565
|
|
|
|
151,960
|
|
Investment in real estate
|
|
|
998
|
|
|
|
1,008
|
|
Total investments for account of policyholders
|
|
|
159,563
|
|
|
|
152,968
|
|
14. Derivatives
There have been no material changes in the composition of the derivative portfolio. The movements in derivative balances mainly result from changes in market conditions.
15. Fair value
The table below provides an
analysis of financial instruments recorded at fair value on a recurring basis by level of the fair value hierarchy:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Fair value hierarchy
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
EUR millions
|
|
Level I
|
|
|
Level II
|
|
|
Level III
|
|
|
Total
|
|
Financial assets carried at fair value available-for-sale
investments
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Shares
|
|
|
244
|
|
|
|
273
|
|
|
|
357
|
|
|
|
874
|
|
Debt securities
|
|
|
22,813
|
|
|
|
71,302
|
|
|
|
2,812
|
|
|
|
96,927
|
|
Money markets and other short-term instruments
|
|
|
-
|
|
|
|
7,065
|
|
|
|
-
|
|
|
|
7,065
|
|
Other investments at fair value
|
|
|
22
|
|
|
|
318
|
|
|
|
869
|
|
|
|
1,209
|
|
March 31, 2013
|
|
|
23,079
|
|
|
|
78,958
|
|
|
|
4,038
|
|
|
|
106,075
|
|
|
|
|
|
|
Fair value through profit or loss
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Shares
|
|
|
1,081
|
|
|
|
107
|
|
|
|
-
|
|
|
|
1,188
|
|
Debt securities
|
|
|
54
|
|
|
|
1,366
|
|
|
|
13
|
|
|
|
1,433
|
|
Money markets and other short-term instruments
|
|
|
740
|
|
|
|
367
|
|
|
|
-
|
|
|
|
1,107
|
|
Other investments at fair value
|
|
|
-
|
|
|
|
591
|
|
|
|
1,445
|
|
|
|
2,036
|
|
Investments for account of policyholders
1
|
|
|
95,101
|
|
|
|
61,695
|
|
|
|
1,769
|
|
|
|
158,565
|
|
Derivatives
|
|
|
35
|
|
|
|
18,681
|
|
|
|
290
|
|
|
|
19,006
|
|
March 31, 2013
|
|
|
97,011
|
|
|
|
82,807
|
|
|
|
3,517
|
|
|
|
183,335
|
|
Total financial assets at fair
value
|
|
|
120,090
|
|
|
|
161,765
|
|
|
|
7,555
|
|
|
|
289,410
|
|
|
|
|
|
|
Financial liabilities carried at fair value
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Investment contracts for account of policyholders
|
|
|
10,865
|
|
|
|
19,944
|
|
|
|
113
|
|
|
|
30,922
|
|
Borrowings
2
|
|
|
525
|
|
|
|
518
|
|
|
|
-
|
|
|
|
1,043
|
|
Derivatives
|
|
|
33
|
|
|
|
14,287
|
|
|
|
2,010
|
|
|
|
16,330
|
|
Total financial liabilities at fair
value
|
|
|
11,423
|
|
|
|
34,749
|
|
|
|
2,123
|
|
|
|
48,295
|
|
1
The investments for account of
policyholders included in the table above represents those investments carried at fair value through profit or loss.
2
Total borrowings on the statement of financial position contain borrowings carried at amortized cost that are not included in the above schedule.
Significant transfers between Level I and II
Aegons policy is to record transfers of assets and liabilities between Level I and Level II at their fair values as of the beginning of each reporting period.
During the first quarter of 2013, the amount of assets and liabilities transferred from Level II to Level I was EUR 493 million. Transfers are identified based on transaction volume and frequency which are indicative of an active market.
The table below shows transfers between Level I and Level II for financial assets and financial liabilities
recorded at fair value on a recurring basis during the three-month period ended March 31, 2013:
|
|
|
|
|
|
|
|
|
Fair value transfers
|
|
|
|
|
|
|
EUR millions
|
|
Transfers
Level I to
Level II
|
|
|
Transfers
Level II to
Level I
|
|
Financial assets carried at fair value available-for-sale
investments
|
|
|
|
|
|
|
|
|
Debt securities
|
|
|
-
|
|
|
|
236
|
|
March 31, 2013
|
|
|
-
|
|
|
|
236
|
|
|
|
|
Fair value through profit or loss
|
|
|
|
|
|
|
|
|
Investments for account of
policyholders
|
|
|
-
|
|
|
|
257
|
|
March 31, 2013
|
|
|
-
|
|
|
|
257
|
|
Total financial assets at fair
value
|
|
|
-
|
|
|
|
493
|
|
Movements in Level III financial instruments measured at fair value
The following table summarize the change of all assets and liabilities measured at estimated fair value on a recurring basis using significant unobservable inputs
(Level III), including realized and unrealized gains (losses) of all assets and liabilities and unrealized gains (losses) of all assets and liabilities still held at the end of the respective period.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Roll forward of Level III financial instruments
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
January 1,
2013
|
|
|
Total gains /
losses in
income
statement
1
|
|
|
Total gains /
losses in OCI
2
|
|
|
Purchases
|
|
|
Sales
|
|
|
Settlements
|
|
|
Net exchange
differences
|
|
|
Transfers from
Level I and
Level II
|
|
|
Transfers to
Level I and
Level II
|
|
|
March 31,
2013
|
|
|
Total gains or losses
for the period included
in
the profit and loss
for instruments held
at March 31, 2013
3
|
|
Financial assets carried at fair value
available-for-sale investments
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Shares
|
|
|
376
|
|
|
|
1
|
|
|
|
1
|
|
|
|
6
|
|
|
|
(25
|
)
|
|
|
(4
|
)
|
|
|
3
|
|
|
|
-
|
|
|
|
(1
|
)
|
|
|
357
|
|
|
|
-
|
|
Debt securities
|
|
|
2,643
|
|
|
|
14
|
|
|
|
43
|
|
|
|
238
|
|
|
|
(67
|
)
|
|
|
(61
|
)
|
|
|
47
|
|
|
|
148
|
|
|
|
(193
|
)
|
|
|
2,812
|
|
|
|
-
|
|
Other investments at fair value
|
|
|
883
|
|
|
|
(27
|
)
|
|
|
33
|
|
|
|
46
|
|
|
|
(86
|
)
|
|
|
(3
|
)
|
|
|
23
|
|
|
|
-
|
|
|
|
-
|
|
|
|
869
|
|
|
|
-
|
|
|
|
|
3,902
|
|
|
|
(12
|
)
|
|
|
77
|
|
|
|
290
|
|
|
|
(178
|
)
|
|
|
(68
|
)
|
|
|
73
|
|
|
|
148
|
|
|
|
(194
|
)
|
|
|
4,038
|
|
|
|
-
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Fair value through profit or loss
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Debt securities
|
|
|
14
|
|
|
|
(1
|
)
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
13
|
|
|
|
(1
|
)
|
Other investments at fair value
|
|
|
1,416
|
|
|
|
44
|
|
|
|
-
|
|
|
|
9
|
|
|
|
(58
|
)
|
|
|
-
|
|
|
|
38
|
|
|
|
12
|
|
|
|
(16
|
)
|
|
|
1,445
|
|
|
|
46
|
|
Investments for account of policyholders
|
|
|
1,715
|
|
|
|
67
|
|
|
|
9
|
|
|
|
174
|
|
|
|
(200
|
)
|
|
|
-
|
|
|
|
(6
|
)
|
|
|
26
|
|
|
|
(16
|
)
|
|
|
1,769
|
|
|
|
55
|
|
Derivatives
|
|
|
301
|
|
|
|
(10
|
)
|
|
|
-
|
|
|
|
1
|
|
|
|
-
|
|
|
|
3
|
|
|
|
(5
|
)
|
|
|
-
|
|
|
|
-
|
|
|
|
290
|
|
|
|
(5
|
)
|
|
|
|
3,446
|
|
|
|
100
|
|
|
|
9
|
|
|
|
184
|
|
|
|
(258
|
)
|
|
|
3
|
|
|
|
27
|
|
|
|
38
|
|
|
|
(32
|
)
|
|
|
3,517
|
|
|
|
95
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Financial liabilities carried at fair value
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Investment contracts for account of policyholders
|
|
|
(109
|
)
|
|
|
(1
|
)
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
(3
|
)
|
|
|
-
|
|
|
|
-
|
|
|
|
(113
|
)
|
|
|
(1
|
)
|
Derivatives
|
|
|
(2,318
|
)
|
|
|
324
|
|
|
|
-
|
|
|
|
(1
|
)
|
|
|
-
|
|
|
|
-
|
|
|
|
(17
|
)
|
|
|
-
|
|
|
|
2
|
|
|
|
(2,010
|
)
|
|
|
324
|
|
|
|
|
(2,427
|
)
|
|
|
323
|
|
|
|
-
|
|
|
|
(1
|
)
|
|
|
-
|
|
|
|
-
|
|
|
|
(20
|
)
|
|
|
-
|
|
|
|
2
|
|
|
|
(2,123
|
)
|
|
|
323
|
|
1
Includes impairments and
movements related to fair value hedges. Gains and losses are recorded in the line item results from financial transactions of the income statement.
2
Total gains and losses are recorded in line items Gains/ (losses) on revaluation of available-for-sale investments and
(Gains)/ losses transferred to the income statement on disposal and impairment of available-for-sale investment of the statement of other comprehensive income.
3
Total gains / (losses) for the period during which the financial instrument was in Level III.
Aegons policy is to record transfers of assets and liabilities between Level I, Level II and Level III at their fair values as of the beginning of each
reporting period. During the first quarter of 2013, Aegon transferred certain financial instruments from Levels I and Level II to Level III of the fair value hierarchy. The reason for the change in level was that the market liquidity for these
securities decreased, which led to a change in market observability of prices. Prior to transfer, the fair value for the Level I and Level II securities was determined using observable market transactions or corroborated broker quotes respectively
for the same or similar instruments. Since the transfer, all such assets have been valued using valuation models incorporating significant non market-observable inputs or uncorroborated broker quotes.
Similarly, during the first quarter in 2013, Aegon transferred certain financial instruments from Level III to other levels of the fair value hierarchy. The change
in level was mainly the result of a return of activity in the market for these securities and that for these securities the fair value could be determined using observable market transactions or corroborated broker quotes for the same or similar
instruments.
The table below presents information about the significant unobservable inputs used for recurring and
non-recurring fair value measurements for certain Level III financial instruments.
|
|
|
|
|
|
|
|
|
|
|
Overview of significant unobservable inputs
|
|
|
|
|
EUR millions
|
|
Carrying
amount March
31, 2013
|
|
|
Valuation technique
1
|
|
Significant unobservable
input
2
|
|
Range (weighted
average)
|
Financial assets carried at fair value available-for-sale
investments
|
|
|
|
|
|
|
|
|
|
|
Shares
|
|
|
202
|
|
|
Broker quote
|
|
n.a.
|
|
n.a.
|
|
|
|
155
|
|
|
Other
|
|
n.a.
|
|
n.a.
|
|
|
|
357
|
|
|
|
|
|
|
|
|
|
|
|
|
Debt securities
|
|
|
|
|
|
|
|
|
|
|
RMBS
|
|
|
250
|
|
|
Broker quote
|
|
n.a.
|
|
n.a.
|
|
|
|
70
|
|
|
Other
|
|
n.a.
|
|
n.a.
|
CMBS
|
|
|
51
|
|
|
Broker quote
|
|
n.a.
|
|
n.a.
|
|
|
|
56
|
|
|
Other
|
|
n.a.
|
|
n.a.
|
ABS
|
|
|
200
|
|
|
Discounted cash flow
|
|
Discount rate
|
|
3% - 8% (6.72%)
|
|
|
|
1,424
|
|
|
Broker quote
|
|
n.a.
|
|
n.a.
|
|
|
|
132
|
|
|
Other
|
|
n.a.
|
|
n.a.
|
Corporate bonds
|
|
|
251
|
|
|
Discounted cash flow
|
|
Credit spread
|
|
0.4% - 4.4% (3.12%)
|
|
|
|
330
|
|
|
Broker quote
|
|
n.a.
|
|
n.a.
|
|
|
|
23
|
|
|
Other
|
|
n.a.
|
|
n.a.
|
Sovereign debt
|
|
|
25
|
|
|
Broker quote
|
|
n.a.
|
|
n.a.
|
|
|
|
2,812
|
|
|
|
|
|
|
|
|
|
|
|
|
Other investments at fair value
|
|
|
|
|
|
|
|
|
|
|
Tax credit investments
|
|
|
714
|
|
|
Discounted cash flow
|
|
Discount rate
|
|
9.91%
|
Other
|
|
|
130
|
|
|
Net asset value
|
|
n.a.
|
|
n.a.
|
|
|
|
25
|
|
|
Other
|
|
n.a.
|
|
n.a.
|
|
|
|
869
|
|
|
|
|
|
|
|
March 31, 2013
|
|
|
4,038
|
|
|
|
|
|
|
|
|
|
|
|
|
Fair value through profit or loss
|
|
|
|
|
|
|
|
|
|
|
Debt securities
|
|
|
13
|
|
|
Other
|
|
n.a.
|
|
n.a.
|
|
|
|
|
|
Other investments at fair value
|
|
|
|
|
|
|
|
|
|
|
Real estate investments
|
|
|
758
|
|
|
Net asset value
|
|
n.a.
|
|
n.a.
|
Private equity investments
|
|
|
657
|
|
|
Net asset value
|
|
n.a.
|
|
n.a.
|
Hedge funds
|
|
|
30
|
|
|
Net asset value
|
|
n.a.
|
|
n.a.
|
|
|
|
1,445
|
|
|
|
|
|
|
|
Derivatives
|
|
|
157
|
|
|
Discounted cash flow
|
|
Mortality
|
|
Aegon 2012-2062 mortality table
|
|
|
|
13
|
|
|
Other
|
|
n.a.
|
|
n.a.
|
|
|
|
170
|
|
|
|
|
|
|
|
March 31, 2013
|
|
|
1,628
|
|
|
|
|
|
|
|
|
|
|
|
|
Total financial assets at fair
value
|
|
|
5,666
|
|
|
|
|
|
|
|
|
|
|
|
|
Financial liabilities carried at fair value
|
|
|
|
|
|
|
|
|
|
|
Derivatives
|
|
|
|
|
|
|
|
|
|
|
Embedded derivatives in insurance contracts
|
|
|
1,840
|
|
|
Discounted cash flow
|
|
Credit spread
|
|
0.65%
|
Other
|
|
|
170
|
|
|
Other
|
|
n.a.
|
|
n.a.
|
Total financial liabilities at fair
value
|
|
|
2,010
|
|
|
|
|
|
|
|
1
Other in the table above (column
Valuation technique) includes investments for which the fair value is uncorroborated and no broker quote is received.
2
Not applicable (n.a.) has been included when no significant unobservable assumption has been identified and used.
Investments for account of policyholders are excluded from the table above and from the disclosure regarding reasonably possible alternative assumptions. Policyholder assets, and their returns, belong to
policyholders and do not impact Aegons net income or equity. The effect on total assets is offset by the effect on total liabilities. Derivatives exclude derivatives for account of policyholders amounting to EUR 120 million.
The valuation techniques included in the table above are described in more detail below:
Shares
When available, Aegon uses quoted market prices in active markets to determine the fair value of its shares. When Aegon cannot make use of quoted market prices,
market prices from indices or quotes from third-party pricing services or brokers are used.
Available-for-sale shares include shares in the Federal
Home Loan Bank for an amount of EUR 111 million that are measured at par, which are reported as part of Other. The bank has implicit financial support from the United States government. The redemption value of the shares is fixed at par and can
only be redeemed by the bank.
Residential mortgage-backed securities (RMBS), commercial mortgage-backed securities (CMBS) and asset backed
securities (ABS)
V
aluations of RMBS, CMBS and ABS are monitored and reviewed on a monthly basis. Valuations are based on a pricing hierarchy
and depending on the asset type the pricing hierarchy consists of a waterfall that starts with making use of market prices from indices and follows with making use of third-party pricing services or brokers. The pricing hierarchy is dependent on the
possibilities of corroboration of the market prices. If no market prices are available Aegon uses internal models to determine fair value. Significant inputs included in the internal models are generally determined based on relative value analyses,
which incorporate comparisons to instruments with similar collateral and risk profiles. Market standard models may be used to model the specific collateral composition and cash flow structure of each transaction. The most significant
unobservable input is illiquidity premium which is embedded in the discount rate
.
Corporate bonds
Valuations of corporate bonds are monitored and reviewed on a monthly basis. The pricing hierarchy is dependent on the possibility of corroboration of market prices
when available. If no market prices are available, valuations are determined by a discounted cash flow methodology using an internally calculated yield. The yield is comprised of a credit spread over a given benchmark. In all cases the benchmark is
an observable input. The credit spread contains both observable and unobservable inputs. Aegon starts by taking an observable credit spread from a similar bond of the given issuer, and then adjust this spread based on unobservable inputs. These
unobservable inputs may include subordination, liquidity and maturity differences.
Tax credit investments
The fair value of tax credit investments is determined by using a discounted cash flow valuation technique. This valuation technique takes into consideration
projections of future capital contributions and distributions, as well as future tax credits and the tax benefits of future operating losses. The present value of these cash flows is calculated by applying a discount rate. In general, the discount
rate is determined based on the cash outflows for the investments and the cash inflows from the tax credits / tax benefits (and the timing of those cash flows). These inputs are unobservable in the market place.
Real estate investments, private equity investments and hedge funds
The fair values of investments held in non-quoted investment funds are determined by management after taking into consideration information provided by the fund managers. Aegon reviews the valuations each month and
performs analytical procedures and trending analyses to ensure the fair values are appropriate.
Sovereign debt
When available, Aegon uses quoted market prices in active markets to determine the fair value of its sovereign debt investments. When Aegon cannot make use of
quoted market prices, market prices from indices or quotes from third-party pricing services or brokers are used.
Derivatives
Where quoted market prices are not available, other valuation techniques, such as option pricing or stochastic modeling, are applied. The valuation techniques
incorporate all factors that a typical market participant would consider and are based on observable market data when available. Models are validated before they are used and calibrated to ensure that outputs reflect actual experience and comparable
market prices.
Fair values for exchange-traded derivatives, principally futures and certain options, are based on quoted market prices in active
markets. Fair values for over-the-counter (OTC) derivative financial instruments represent amounts estimated to be received from or paid to a third party in settlement of these instruments. These derivatives are valued using pricing models based on
the net present value of estimated future cash flows, directly observed prices from exchange-traded derivatives, other OTC trades, or external pricing services. Most valuations are derived from swap and volatility matrices, which are constructed for
applicable indices and currencies using current market data from many industry standard sources. Option pricing is based on industry standard valuation models and current market levels, where applicable. The pricing of complex or illiquid
instruments is based on internal models or an independent third party. For long-dated illiquid contracts, extrapolation methods are applied to observed market data in order to estimate inputs and assumptions that are not directly observable. To
value OTC derivatives, management uses observed market information, other trades in the market and dealer prices.
Aegon normally mitigates counterparty
credit risk in derivative contracts by entering into collateral agreements where practical and in ISDA master netting agreements for each of the Groups legal entities to facilitate Aegons right to offset credit risk exposure. Changes in
the fair value of derivatives attributable to changes in counterparty credit risk were not significant.
Embedded derivatives in insurance contracts
including guarantees
Certain bifurcated guarantees for minimum benefits in insurance and investment contracts are carried at fair value. These
guarantees include guaranteed minimum withdrawal benefits (GMWB) in the United States, United Kingdom and Japan which are offered on some variable annuity products and are also assumed from a ceding company; minimum interest rate guarantees on
insurance products offered in the Netherlands, including group pension and traditional products; variable annuities sold in Europe and Japan, and guaranteed minimum accumulation benefits on segregated funds sold in Canada.
Since the price of these guarantees is not quoted in any market, the fair values of these guarantees are calculated as the present value of future expected
payments to policyholders less the present value of assessed rider fees attributable to the guarantees. Given the complexity and long-term nature of these guarantees which are unlike instruments available in financial markets, their fair values are
determined by using stochastic techniques under a variety of market return scenarios. A variety of factors are considered including credit spread, expected market rates of return, equity and interest rate volatility, correlations of market returns,
discount rates and actuarial assumptions. The most significant unobservable factor is credit spread.
The expected returns are based on risk-free rates.
Aegon added a premium to reflect the credit spread as required. The credit spread is set by using the credit default swap (CDS) spreads of a reference portfolio of life insurance companies (including Aegon), adjusted to reflect the subordination of
senior debt holders at the holding company level to the position of policyholders at the operating company level (who have priority in payments to other creditors). Aegons assumptions are set by region to reflect differences in the valuation
of the guarantee embedded in the insurance contracts.
Assumptions are reviewed at each valuation date, and updated based on historical experience and
observable market data, including market transactions such as acquisitions and reinsurance transactions. Assumptions regarding policyholder behavior, such as lapses, included in the models are derived in the same way as the assumptions used to
measure insurance liabilities.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Effect
of reasonably possible alternative assumptions
|
|
|
|
|
|
|
|
EUR millions
|
|
Carrying
amount March
31, 2013
|
|
|
Significant unobservable
input
|
|
Note
|
|
|
Effect of reasonably possible
alternative assumptions (+/-)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
increase
|
|
|
|
decrease
|
|
Financial assets carried at fair value available-for-sale
investments
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Debt securities
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
ABS
|
|
|
200
|
|
|
Discount rate
|
|
|
a
|
|
|
|
21
|
|
|
|
(21
|
)
|
Corporate bonds
|
|
|
251
|
|
|
Credit spread
|
|
|
b
|
|
|
|
20
|
|
|
|
(17
|
)
|
|
|
|
|
|
|
Other investments at fair value
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Tax credit investments
|
|
|
714
|
|
|
Discount rate
|
|
|
c
|
|
|
|
13
|
|
|
|
(12
|
)
|
|
|
|
|
|
|
Fair value through profit or loss
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Derivatives
|
|
|
157
|
|
|
Mortality
|
|
|
d
|
|
|
|
15
|
|
|
|
(12
|
)
|
|
|
|
|
|
|
Financial liabilities carried at fair value
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Embedded derivatives in insurance
contracts
|
|
|
1,840
|
|
|
Credit spread
|
|
|
e
|
|
|
|
111
|
|
|
|
(105
|
)
|
The table above presents the impact on a fair value measurement of a change in an unobservable input. The impact of changes in
inputs may not be independent, therefore the descriptions provided below indicate the impact of a change in an input in isolation.
a)
|
The primary unobservable assumptions used in fair value measurement of asset backed securities is in general a liquidity premium in the discount rate. Changing the liquidity
premium changes the discount rate when using the discounted cash flow model. Increasing or decreasing the liquidity premium respectively decreases or increases the value of the investment. Aegon adjusted the discount rate with 100 basis points up or
down for this input.
|
b)
|
For corporate bonds the most significant unobservable input for the valuation of these securities is the credit spread. An increase in credit spread results in a lower valuation,
while a decrease in credit spread results in a higher valuation. Aegon adjusted the discount rate by 50 basis points up or down for this input.
|
c)
|
Tax credit investments are measured at fair value using an internal model. The most significant unobservable input for valuation of these tax credits is the discount rate.
Increasing or decreasing the discount rate would result in respectively a lower or higher valuation. Aegon adjusted the discount rate by 50 basis points up or down for this input.
|
d)
|
The derivative included is a longevity index derivative of Aegon the Netherlands. Most significant unobservable inputs are mortality tables. The mortality table used to determine
the fair value of this derivative is the projected Aegon 2012-2062 table. Changing the mortality rates changes the cash flow expectations from this derivative. Increasing (decreasing) the mortality rates decreases (increases) the value of the
investment. Aegon adjusted longevity with 2% up or down for this input, compared to the prospective mortality table in determining the value of this derivative.
|
e)
|
To determine the fair value of the bifurcated embedded derivatives related to guarantees, a discount rate is used including credit spread. An increase in the credit spread
results in lower valuation, while a decrease results in a higher valuation of the embedded derivatives. Aegon increased or decreased the credit spread by 20 basis points.
|
Fair value information about financial instruments not measured at fair value
The following table presents the carrying values and estimated fair values of financial assets and liabilities, excluding financial instruments which are carried at
fair value on a recurring basis.
|
|
|
|
|
|
|
|
|
Fair
value information about financial instruments not measured at fair value
|
|
EUR millions
|
|
Carrying
amount March
31, 2013
|
|
|
Total
estimated fair
value March
31, 2013
|
|
|
|
|
Assets
|
|
|
|
|
|
|
|
|
Mortgage loans - held at amortized cost
|
|
|
28,851
|
|
|
|
33,704
|
|
Private loans - held at amortized cost
|
|
|
1,005
|
|
|
|
1,096
|
|
Other loans - held at amortized
cost
|
|
|
2,373
|
|
|
|
2,374
|
|
|
|
|
Liabilities
|
|
|
|
|
|
|
|
|
Trust pass-through securities - held at amortized cost
|
|
|
156
|
|
|
|
132
|
|
Subordinated borrowings - held at amortized cost
|
|
|
44
|
|
|
|
64
|
|
Borrowings held at amortized
cost
|
|
|
12,898
|
|
|
|
13,265
|
|
Financial instruments for which carrying value approximates fair value
Certain financial instruments that are not carried at fair value are carried at amounts that approximate fair value, due to their short-term nature and generally
negligible credit risk. These instruments include cash and cash equivalents, short-term receivables and accrued interest receivable, short-term liabilities, and accrued liabilities. These instruments are not included in the table above.
16. Deferred expenses and rebates
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
EUR millions
|
|
|
Mar. 31, 2013
|
|
|
|
Dec. 31, 2012
|
|
|
|
|
DPAC for insurance contracts and investment contracts with discretionary
participation features
|
|
|
10,909
|
|
|
|
10,681
|
|
Deferred cost of reinsurance
|
|
|
551
|
|
|
|
558
|
|
Deferred transaction costs for investment
management services
|
|
|
408
|
|
|
|
405
|
|
Total deferred expenses and
rebates
|
|
|
11,868
|
|
|
|
11,644
|
|
17. Share capital
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
EUR millions
|
|
|
Mar. 31, 2013
|
|
|
|
Dec. 31, 2012
|
|
|
|
|
Share capital - par value
|
|
|
319
|
|
|
|
319
|
|
Share premium
|
|
|
8,780
|
|
|
|
8,780
|
|
Total share capital
|
|
|
9,099
|
|
|
|
9,099
|
|
|
|
|
Share capital - par value
|
|
|
|
|
|
|
|
|
Balance at January 1
|
|
|
319
|
|
|
|
310
|
|
Issuance
|
|
|
-
|
|
|
|
2
|
|
Share dividend
|
|
|
-
|
|
|
|
7
|
|
Balance
|
|
|
319
|
|
|
|
319
|
|
|
|
|
Share premium
|
|
|
|
|
|
|
|
|
Balance at January 1
|
|
|
8,780
|
|
|
|
8,787
|
|
Share dividend
|
|
|
-
|
|
|
|
(7
|
)
|
Balance
|
|
|
8,780
|
|
|
|
8,780
|
|
Diluted earnings per share
Diluted earnings per share is calculated by adjusting the average number of shares outstanding for share options. In Q1 2013 and 2012, the average share price did
not exceed the exercise price of these options. As a result diluted earnings per share does not differ from basic earnings per share.
18. Borrowings
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
EUR millions
|
|
Mar. 31, 2013
|
|
|
Dec. 31, 2012
|
|
|
|
|
Debentures and other loans
|
|
|
13,367
|
|
|
|
13,219
|
|
Commercial paper
|
|
|
364
|
|
|
|
413
|
|
Short-term deposits
|
|
|
17
|
|
|
|
17
|
|
Bank overdrafts
|
|
|
193
|
|
|
|
93
|
|
Total borrowings
|
|
|
13,941
|
|
|
|
13,742
|
|
Debentures and other loans
Included in Debentures and other loans is EUR 1,043 relating to borrowings measured at fair value (2012: EUR 1,050).
Commercial paper, Short term deposits and Bank overdrafts vary with the normal course of business.
19. Offsetting, enforceable master netting arrangements and similar agreements
The following
table provides details relating to the effect or potential effect of netting arrangements, including rights of set-off associated with the entitys recognized financial assets and recognized financial liabilities.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Financial assets subject to offsetting, enforceable master netting arrangements and
similar agreements
|
|
|
|
|
|
|
|
|
|
|
|
|
Related amounts not set off in the statements of
financial
position
|
|
|
|
|
EUR millions
|
|
Gross amounts of
recognized financial
assets
|
|
|
Gross amounts of
recognized financial
liabilities set off in
the
statement of financial
position
|
|
|
Net amounts of
financial assets
presented in the
statement of
financial
position
|
|
|
Financial instruments
|
|
|
Cash collateral received
(excluding surplus
collateral)
|
|
|
Net amount
|
|
Derivatives
|
|
|
18,882
|
|
|
|
39
|
|
|
|
18,842
|
|
|
|
14,077
|
|
|
|
4,222
|
|
|
|
543
|
|
March 31, 2013
|
|
|
18,882
|
|
|
|
39
|
|
|
|
18,842
|
|
|
|
14,077
|
|
|
|
4,222
|
|
|
|
543
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Financial liabilities subject to offsetting, enforceable master netting
arrangements and similar agreements
|
|
|
|
|
|
|
|
|
|
|
|
|
Related amounts not set off in the statements of
financial
position
|
|
|
|
|
EUR millions
|
|
Gross amounts of
recognized financial
liabilities
|
|
|
Gross amounts of
recognized financial
assets set off in
the
statement of financial
position
|
|
|
Net amounts of
financial liabilities
presented in
the
statement of financial
position
|
|
|
Financial instruments
|
|
|
Cash collateral pleged
(excluding surplus
collateral)
|
|
|
Net amount
|
|
Derivatives
|
|
|
14,289
|
|
|
|
39
|
|
|
|
14,250
|
|
|
|
13,969
|
|
|
|
2
|
|
|
|
279
|
|
March 31, 2013
|
|
|
14,289
|
|
|
|
39
|
|
|
|
14,250
|
|
|
|
13,969
|
|
|
|
2
|
|
|
|
279
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Financial assets subject to offsetting, enforceable master netting arrangements and
similar agreements
|
|
|
|
|
|
|
|
|
|
|
|
|
Related amounts not set off in the statements of
financial
position
|
|
|
|
|
EUR millions
|
|
Gross amounts of
recognized financial
assets
|
|
|
Gross amounts of
recognized financial
liabilities set off in
the
statement of financial
position
|
|
|
Net amounts of
financial assets
presented in
the
statement of financial
position
|
|
|
Financial instruments
|
|
|
Cash collateral received
(excluding surplus
collateral)
|
|
|
Net amount
|
|
Derivatives
|
|
|
20,776
|
|
|
|
40
|
|
|
|
20,736
|
|
|
|
15,584
|
|
|
|
4,686
|
|
|
|
466
|
|
December 31, 2012
|
|
|
20,776
|
|
|
|
40
|
|
|
|
20,736
|
|
|
|
15,584
|
|
|
|
4,686
|
|
|
|
466
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Financial liabilities subject to offsetting, enforceable master netting
arrangements and similar agreements
|
|
|
|
|
|
|
|
|
|
|
|
|
Related amounts not set off in the statements of
financial position
|
|
|
|
|
EUR millions
|
|
Gross amounts of
recognized financial
liabilities
|
|
|
Gross amounts of
recognized financial
assets set off in
the
statement of financial
position
|
|
|
Net amounts of
financial liabilities
presented in
the
statement of financial
position
|
|
|
Financial instruments
|
|
|
Cash collateral pleged
(excluding surplus
collateral)
|
|
|
Net amount
|
|
Derivatives
|
|
|
15,471
|
|
|
|
40
|
|
|
|
15,431
|
|
|
|
15,099
|
|
|
|
2
|
|
|
|
329
|
|
December 31, 2012
|
|
|
15,471
|
|
|
|
40
|
|
|
|
15,431
|
|
|
|
15,099
|
|
|
|
2
|
|
|
|
329
|
|
Financial assets and liabilities are offset in the statement of financial position when the Group has a legally
enforceable right to offset and has the intention to settle the asset and liability on a net basis, or to realize the asset and settle the liability simultaneously.
Aegon mitigates credit risk in derivative contracts by entering into collateral agreements, where practical, and in ISDA master netting agreements for each of the Aegons legal entities to facilitate
Aegons right to offset credit risk exposure. The credit support agreement will normally dictate the threshold over which collateral needs to be pledged by Aegon or its counterparty. Transactions requiring Aegon or its counterparty to post
collateral are typically the result of over-the-counter derivative trades, comprised mostly of interest rate swaps, currency swaps and credit swaps. These transactions are conducted under terms that are usual and customary to standard long-term
borrowing, derivative, securities lending and securities borrowing activities, as well as requirements determined by exchanges where the bank acts as intermediary.
20. Commitments and contingencies
On March 26, 2013, Aegon signed an agreement with a
third party to sell class A mortgage backed securities (RMBS) amounting to EUR 750 million. These securities consist of two tranches:
t
|
|
EUR 100 million of class A1 notes with an expected weighted average life of two years and priced with a coupon of three month Euribor plus 0.40%; and
|
t
|
|
EUR 650 million of class A2 notes with an expected weighted average life of five years and priced with a coupon of three month Euribor plus 0.82%.
|
The transaction was settled on May 3, 2013.
There have been no other material changes in contingent assets and liabilities as reported in the 2012 consolidated financial statements of Aegon.
21. Acquisitions / Divestments
On December 5, 2012, Aegon announced the acquisition of
100% of Fidem Life, a life insurance company in Ukraine. The transaction was closed on February 8, 2013. Fidem Life is rebranded Aegon Ukraine and is integrated into the governance and management structure of Aegon CEE.
22. Events after the balance sheet date
On
May 3, 2013, Aegon announced that it has reached an agreement with Banco Sabadell to sell its 50% stake in its life insurance partnership originally established with Caja de Ahorros del Mediterráneo (CAM) for a consideration of EUR 449.5
million. The transaction with Banco Sabadell is expected to close in the third quarter of 2013, subject to regulatory approval. The sale is expected to result in a book gain of approximately EUR 75 million.
There were no events after the balance sheet date with a significant impact on the financial position of the Company per March 31, 2013.
[This page intentionally left blank.]
Disclaimers
Cautionary note regarding non-IFRS measures
This document includes the non-IFRS financial measures: underlying
earnings before tax, income tax and income before tax. These non-IFRS measures are calculated by consolidating on a proportionate basis Aegons joint ventures and associated companies. The reconciliation of these measures to the most
comparable IFRS measures is provided in note 3 Segment information of Aegons condensed consolidated interim financial statements. Aegon believes that its non-IFRS measures, together with the IFRS information, provide meaningful
information about the underlying operating results of Aegons business including insight into the financial measures that senior management uses in managing the business.
Local currencies and constant currency exchange rates
This document contains certain information about Aegon
presented in USD for the Americas and GBP for the United Kingdom, because those businesses operate and are managed primarily in those currencies. None of this information is a substitute for or superior to financial information about Aegon presented
in EUR, which is the currency of Aegons primary financial statements.
Forward-looking statements
The statements contained in this document that are not historical facts are forward-looking statements as defined in the US Private Securities Litigation Reform Act
of 1995. The following are words that identify such forward-looking statements: aim, believe, estimate, target, intend, may, expect, anticipate, predict, project, counting on, plan, continue, want, forecast, goal, should, would, is confident, will,
and similar expressions as they relate to Aegon. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Aegon undertakes no obligation to publicly update or revise
any forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which merely reflect company expectations at the time of writing. Actual results may differ materially from expectations conveyed
in forwardlooking statements due to changes caused by various risks and uncertainties. Such risks and uncertainties include but are not limited to the following:
t
|
|
Changes in general economic conditions, particularly in the United States, the Netherlands and the United Kingdom.
|
t
|
|
Changes in the performance of financial markets, including emerging markets, such as with regard to:
|
|
|
The frequency and severity of defaults by issuers in Aegons fixed income investment portfolios;
|
|
|
The effects of corporate bankruptcies and/or accounting restatements on the financial markets and the resulting decline in the value of equity and debt securities Aegon holds;
and
|
|
|
The effects of declining creditworthiness of certain private sector securities and the resulting decline in the value of sovereign exposure that Aegon holds.
|
t
|
|
Changes in the performance of Aegons investment portfolio and decline in ratings of Aegons counterparties.
|
t
|
|
Consequences of a potential (partial) break-up of the euro.
|
t
|
|
The frequency and severity of insured loss events.
|
t
|
|
Changes affecting mortality, morbidity, persistence and other factors that may impact the profitability of Aegons insurance products.
|
t
|
|
Reinsurers to whom Aegon has ceded significant underwriting risks may fail to meet their obligations.
|
t
|
|
Changes affecting interest rate levels and continuing low or rapidly changing interest rate levels.
|
t
|
|
Changes affecting currency exchange rates, in particular the EUR/USD and EUR/GBP exchange rates.
|
t
|
|
Changes in the availability of, and costs associated with, liquidity sources such as bank and capital markets funding, as well as conditions in the credit
markets in general such as changes in borrower and counterparty creditworthiness.
|
t
|
|
Increasing levels of competition in the United States, the Netherlands, the United Kingdom and emerging markets.
|
t
|
|
Changes in laws and regulations, particularly those affecting Aegons operations, ability to hire and retain key personnel, the products Aegon sells, and
the attractiveness of certain products to its consumers.
|
t
|
|
Regulatory changes relating to the insurance industry in the jurisdictions in which Aegon operates.
|
t
|
|
Changes in customer behavior and public opinion in general related to, among other things, the type of products also Aegon sells, including legal, regulatory or
commercial necessity to meet changing customer expectations.
|
t
|
|
Acts of God, acts of terrorism, acts of war and pandemics.
|
t
|
|
Changes in the policies of central banks and/or governments.
|
t
|
|
Lowering of one or more of Aegons debt ratings issued by recognized rating organizations and the adverse impact such action may have on Aegons
ability to raise capital and on its liquidity and financial condition.
|
t
|
|
Lowering of one or more of insurer financial strength ratings of Aegons insurance subsidiaries and the adverse impact such action may have on the premium
writings, policy retention, profitability and liquidity of its insurance subsidiaries.
|
t
|
|
The effect of the European Unions Solvency II requirements and other regulations in other jurisdictions affecting the capital Aegon is required to
maintain.
|
t
|
|
Litigation or regulatory action that could require Aegon to pay significant damages or change the way Aegon does business.
|
t
|
|
As Aegons operations support complex transactions and are highly dependent on the proper functioning of information technology, a computer system failure
or security breach may disrupt Aegons business, damage its reputation and adversely affect its results of operations, financial condition and cash flows.
|
t
|
|
Customer responsiveness to both new products and distribution channels.
|
t
|
|
Competitive, legal, regulatory, or tax changes that affect profitability, the distribution cost of or demand for Aegons products.
|
t
|
|
Changes in accounting regulations and policies may affect Aegons reported results and shareholders equity.
|
t
|
|
The impact of acquisitions and divestitures, restructurings, product withdrawals and other unusual items, including Aegons ability to integrate
acquisitions and to obtain the anticipated results and synergies from acquisitions.
|
t
|
|
Catastrophic events, either manmade or by nature, could result in material losses and significantly interrupt Aegons business.
|
t
|
|
Aegons failure to achieve anticipated levels of earnings or operational efficiencies as well as other cost saving initiatives.
|
Further details of potential risks and uncertainties affecting the company are described in the companys filings with the
Netherlands Authority for the Financial Markets and the US Securities and Exchange Commission, including the Annual Report. These forward-looking statements speak only as of the date of this document. Except as required by any applicable law or
regulation, the company expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the companys expectations with regard thereto or
any change in events, conditions or circumstances on which any such statement is based.
Corporate and shareholder information
|
|
|
|
|
Headquarters
|
|
|
|
|
|
|
|
Aegon N.V.
|
|
|
|
|
|
|
|
P.O. Box 85
|
|
|
|
|
|
|
|
2501 CB The Hague
|
|
|
|
|
|
|
|
The Netherlands
|
|
|
|
|
|
|
|
Telephone
|
|
+ 31 (0) 70 344 32 10
|
|
|
|
|
|
aegon.com
|
|
|
|
|
Group Corporate Communications & Investor Relations
|
|
|
|
|
Media relations
|
|
|
|
|
|
|
|
Telephone
|
|
+ 31 (0) 70 344 89 56
|
|
|
|
|
|
E-mail
|
|
gcc@aegon.com
|
|
|
|
|
|
Investor relations
|
|
|
|
|
|
|
|
Telephone
|
|
+ 31 (0) 70 344 83 05
|
|
|
|
|
|
or
|
|
877 548 96 68 - toll free, USA only
|
|
|
|
|
|
E-mail
|
|
ir@aegon.com
|
|
|
Publication dates quarterly results
|
|
|
|
|
|
|
|
Thursday, August 8, 2013
|
|
Results second quarter 2013
|
|
|
|
|
|
Thursday, November 7, 2013
|
|
Results third quarter 2013
|
|
|
Aegons Q1 2013 press release and Financial supplement are available on
aegon.com.
About Aegon
As an international life insurance, pensions and asset management company based in The Hague, Aegon has businesses in over 20 markets in the Americas, Europe and Asia. Aegon companies employ approximately 24,000
people and have millions of customers across the globe. Further information: aegon.com.